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ABSTRACT
BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF THE 
PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)
John K. Troyer 
Old Dominion University 
and
Eastern Virginia Medical School 
1995
Director: Dr. George L. Wright Jr.
Prostate cancer is the most common malignancy and the second leading cause of 
cancer death in males in the United States. Additionally, the number of deaths 
attributed to prostate cancer is increasing at a rate of approximately 8% a year. 
Development of new diagnostic and therapy strategies are needed in order to 
improve the life expectancy of patients with this disease. One tool which may 
allow for improvements in prostate cancer diagnosis and therapy is the monoclonal 
antibody (MAb) 7E11-C5.3 which was first described in 1987. Since then, the 
antigen recognized by MAb 7E11-C5.3 has been named the prostate specific 
membrane antigen or PSMA. Antibody-radionuclide conjugates of 7E11-C5.3 
have been successfully used to localize metastatic disease in vivo and treat human 
prostate tumors in nude mice suggesting that PSMA may have promise as an 
important new diagnostic and therapeutic tool for prostate cancer. Many questions 
remain to be answered however, regarding the basic biology of MAb 7E11-C5.3 
and PSMA before the true potential of this new marker is known. The present 
study has attempted to answer these questions utilizing a comprehensive 
characterization of PSMA at the biochemical, physical and molecular level.
PSMA was found to be localized at the inner face of the plasma membrane and 
within mitochondria in LNCaP cells. The MAb 7E11-C5.3 epitope was
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determined to consist of only the peptide backbone of PSMA and localized to the 
intracellular domain with a minimal reactive peptide of 6 amino acids 
(MWNLLH). PSMA was detected in normal, benign and malignant prostate 
tissues as well as normal small intestine, brain and salivary gland indicating that 
this marker is not as specific as once thought. Additionally, PSMA was detected 
in seminal fluid but not in serum using MAb 7E11-C5.3. Finally, the promoter of 
the PSMA gene was cloned upstream of a reporter gene construct which was 
expressed in androgen and androgen receptor free conditions indicating that the 
regulation of PSMA is markedly different from that of the prostate specific antigen 
(PSA). This study has provided a solid foundation on which to build a more 
thorough understanding of MAb 7E11-C5.3 based imaging and therapy 
applications and continues to suggest that PSMA is a novel and important new 
prostate biomarker.
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1CHAPTER I 
INTRODUCTION
A. REVIEW OF THE LITERATURE
Prostate cancer is the most common malignancy and the second leading 
cause of cancer death in males. It is estimated that 244,000 males will be 
diagnosed with this disease and 40,400 will die of prostate cancer in 1995 (1). In 
other words, every male in the United States has a 10% probability of contracting 
prostate cancer in his lifetime. Undoubtedly, as the population continues to age, 
prostate cancer will become an increasing medical problem. Prostate 
adenocarcinoma is unique in that it exists as two distinct clinical entities; a latent 
or histological cancer and a clinically evident cancer (2). Latent tumors are 
usually not clinically manifested nor detected in men until autopsy, meaning they 
die with their tumors instead of from them. In contrast, clinically diagnosed 
prostate adenocarcinoma is often aggressive and highly metastatic (2). One of the 
major goals in the study of prostate biomarkers is not to detect all prostate tumors, 
but just those which are clinically important. This specificity will allow clinicians 
to specifically treat patients with clinically significant disease and permit patients 
with latent cancer to continue living an otherwise healthy life. As with any 
malignancy, the key to managing this disease is early detection and treatment of 
these aggressive tumors to reduce both morbidity and mortality (3,4).
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2In many human tumors, the progression from the normal cellular state to 
benign hyperplasia to preneoplastic lesions then to carcinoma in situ can be 
followed by observing the set of genetic mutations which have accumulated. The 
classic example of this observation is the monoclonal progression o f colorectal 
carcinoma described by Fearon and Vogelstein. In this model, an accumulation of 
genetic changes including mutations or loss of the APC gene, mutations of 
oncognenes (K-ras), loss or inactivation of tumor suppressor genes such as the 
DCC gene and p53, as well as DNA hypomethylation occur as tumorigenesis 
proceeds from benign disease to metastatic carcinoma (5,6). In the past ten years it 
has been recognized that many oncogenes and tumor suppressor genes are mutated 
or deleted in human tumors. In contrast, a clear pattern of genetic alterations has 
not been found in the progression of prostate pathology from the normal prostate 
to benign prostatic hyperplasia (BPH) to prostatic intraepithelial neoplasia (PIN) to 
prostate adenocarcinoma (CaP). In fact, it is unclear whether a progression exists 
or whether these pathologies represent independent disease processes. For 
example, the combined data from three independent studies showed that less than 
4% of prostate samples analyzed contained Ha-ras mutations (7-9). The 
importance of Rb gene inactivation in prostate carcinoma has been suggested 
(10,11) but is not overwhelmingly significant with 11 of 41 informative tumors 
(27%) showing loss of heterozygosity at the Rb gene locus while the frequency of 
the p53 mutations is a relatively infrequent event (10-15%) when compared to 
many other common cancers (12,13), although bone metastatic prostate tumors 
may have an increased percentage of p53 mutations indicating that they are late 
events in the progression of prostate tumors (14-16). While it is evident that these 
mutations may play a role in the progression of prostate pathology, it is obvious 
that few of the known genetic alterations will be useful for the detection and 
diagnosis of this disease and of little use in differentiating latent from aggressive
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
3tumors. This fact and the recent controversy regarding whether and when to treat 
prostate cancer patients (17) and which treatment modality to use, suggests that 
additional biomarkers need to be identified in order to more accurately 
differentiate benign from malignant prostate disease, to identify the clinically 
important prostate carcinomas, and to develop potential targets for new treatment 
strategies.
Several prostate biomarkers have been identified and have proven to be 
clinically useful. The first of these markers was prostatic acid phosphatase (PAP), 
identified in 1938 (18). Prostatic acid phosphatase is a secretory product of the 
normal prostate gland and can be measured in the serum o f patients with 
extracapsular prostate adenocarcinoma. Since an elevated serum PAP level is 
indicative of metastatic disease and contraindicates a radical prostatectomy, a 
serum PAP assay was utilized for many years to determine if extraprostatic disease 
was present prior to surgery (19).
The most useful biomarker in all of cancer biology is the prostate specific 
antigen (PSA) (20). While at the time of its identification PSA appeared to be only 
expressed by the prostate gland in males, it is not nearly as prostate specific as 
originally thought. Several studies have recently shown PSA to be present in 
breast, colon, ovarian, parotid, kidney and liver tumors, normal breast, amniotic 
fluid and breast milk (21), as well as normal salivary gland (22) and normal 
endometrium (23). Like PAP, PSA is a secretory product of the prostate and is 
normally confined to the genitourinary tract and cannot be detected in the serum. 
Damage to the prostate vasculature during prostatitis or benign hyperplasia results 
in a moderate leakage of PSA into the blood stream (0-10 ng/ml) and extracapsular 
prostate adenocarcinoma causes a dramatic increase in serum PSA values (10- 
>1,000 ng/ml). With the advent in recent years of highly sensitive serum PSA 
measurements (25,26), the detection rate of prostate adenocarcinoma has been
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
4markedly enhanced when combined with a digital rectal exam (DRE). The 
combined use of DRE and serum PSA measurement is now considered to be the 
optimum diagnostic protocol for the detection of prostate adenocarcinoma (27).
An elevated serum PSA level does correlate with poor prognosis and some have 
suggested the use of a DRE and serum PSA values to screen males for BPH and 
CaP. However, approximately 30% of BPH patients give false positive PSA levels 
and 25-30% of prostate cancer patients have normal serum PSA concentrations 
(27-29). It is clear that although PSA is a very useful marker of prostate 
pathology, there is much room for improvement.
Various other markers of prostate disease have been reported including 
clinical and pathological markers such as apoptotic index (30), tumor stage (31) 
and volume (32); proliferative markers including PCNA (33), Ki-67 (34), and 
mitotic index; nuclear morphometric analysis (35); the neuroendocrine markers 
neuron specific enolase, chromogranins, and bombesin (36); mutations and 
expression of the androgen receptor (37-39); epithelial-stromal cell interactions 
with E-cadherin (40), type VII collagen and laminin receptors (41); blood group 
antigens (42); mucins such as PD-41 (43); ploidy analysis utilizing flow 
cytometry and image analysis techniques (44); and other markers including 
prostate secretory protein (PSP) (45), Turp-27 (46,47), PR92 (48), cathepsin D 
(49), PR-1 (50), Leu-7 (51), nucleoside diphosphate kinase (nm23) (52), fatty acid 
synthase (53), and bcl-2 expression (54) are being evaluated for efficacy as 
prostate biomarkers. Notably, PSP can be detected in seminal plasma and urine of 
prostate cancer patients but does not correlate with prostate cancer stage and grade 
as well as PSA (55,56). The PD-41 MAb which recognizes a mucin called 
prostate mucin antigen (PMA) appears to be the only marker identified to date 
which is specific for prostate carcinoma unlike the majority of the markers which 
react to normal, BPH and CaP. The c-erbB-2/neu oncogene is highly
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
5overexpressed in breast adenocarcinoma and has been reported to be prevalent in 
human prostate cancer (57-59) but its level of expression and subcellular 
localization must be critically addressed before it is known whether it will have 
any prognostic value for prostatic carcinoma. While many of these markers have 
either not been fully investigated or not proven to be highly significant when 
analyzed alone, a panel of several of these markers analyzed concurrently may 
provide a useful measure of the status of prostatic disease.
The primary treatment for prostate cancer is prostatectomy and orchiectomy 
in the form of physical or chemical castration (60) which removes the primary 
source of testosterone from the pituitary to gonadal axis (61). One of the most 
important and highly debated decisions confronted by the physician treating 
prostate carcinoma is whether a prostatectomy should be performed (62,63). The 
main parameter regarding this decision is whether there is extraprostatic disease or 
if  the tumor remains organ confined. It is generally agreed that a radical 
prostatectomy is most advantageous to patients with organ confined disease but of 
little use, and actually to the detriment, of patients with extracapsular disease (64). 
Since serum PSA values are predictive of metastatic dissemination of prostate 
carcinoma, they are utilized to determine the extent of disease. However, as noted 
above, there are significant false positive and false negative results. A precise 
clinical tool which would definitively determine the presence or absence of 
extraprostatic disease may be of use in this clinical decision in cases where there is 
no clear evidence of micrometastatic spread. The identification of micrometastatic 
foci prior to surgery would spare patients with metastatic disease the risks and 
complications of radical prostatectomy. These patients could then be more 
appropriately treated with chemotherapy and radiation protocols since it is 
doubtful they would receive any benefit from a radical prostatectomy.
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6One of the significant problems which must be addressed in this and other 
studies of prostate biomarkers is that many prostate genes are highly regulated by 
androgens (65). Androgen regulated gene expression is important in normal male 
development and is mediated by the androgen receptor (AR) (66,67). The 
androgen receptor belongs to a family of steroid receptors including the 
glucocorticoid and progesterone receptors which are localized in the cytoplasm. 
The hydrophobic nature of steroid hormones allows them to traverse the 
phospholipid bilayer o f cell membranes and interact with their receptors in the 
cytoplasm. Following ligand binding, the receptor-ligand complex moves to the 
nucleus where it is capable of binding to specific DNA sequences, or hormone 
responsive elements (HRE), and acts as a transcription factor (68,69). 
Interestingly, several hormones can bind and activate these receptors. For 
example, testosterone will bind and activate the AR, but the testosterone 
metabolite dihydroxytestosterone (DHT) has approximately ten times greater 
affinity for the AR than testosterone (70,71).
Not only do androgens play an important role during male development, 
they are also integral in maintaining the normal structure and function of the 
prostate gland throughout the life of an adult (72,73). Removal of androgen 
hormones either physically or chemically, results in the involution of the prostate 
via induction of apoptosis, or programmed cell death, as indicated by the fact that 
expression of the prostatic cell death gene, TRPM-2, is induced by castration (61). 
This involution of the prostate gland forms the basis for orchiectomy as one of the 
primary treatments for prostate adenocarcinoma.
The prostate specific antigen is a prime example of a gene which is only 
expressed in the presence of androgen hormones (74-78). A dramatic decrease in 
serum PSA values is observed in prostate cancer patients following androgen 
ablation and may drop from >1,000 ng/ml to near 0 ng/ml (29). A small promoter
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
7fragment (300 bp) from the PSA gene inserted in front of a chloramphenicol acetyl 
transferase (CAT) reporter gene proved that this gene is upregulated in the 
presence of androgen hormones (79,80).
While the prostate gland does dramatically shrink in size and tumors cease 
to grow following hormone ablation, the majority of prostate tumors become 
androgen independent and begin to proliferate again several years subsequent to 
orchiectomy. In many cases PSA is also expressed in the absence of androgens 
and can be detected in the serum. One possible cause of this renewed tumor 
growth and PSA expression may be point mutations in the androgen receptor 
which allow binding and activation by multiple steroid hormones including 
estrogen, progesterone and some androgen receptor antagonists (37-39). However, 
it is reasonable to suggest that a significant percentage of prostate tumors may 
begin to proliferate following androgen ablation without an increase in PSA 
expression. In fact, a recent report suggests that some androgen independent 
tumors may produce factors which suppress PSA expression (81). Such tumors 
would escape detection by serum PSA measurement and would not be discovered 
until more acute symptoms of metastatic disease become evident such as bone pain 
and lymph node enlargement. Additionally, an alternative pathway for PSA 
expression has been suggested in LNCaP cells in the absence of steroid hormones 
(82) which could result in an increase in serum PSA values without a concomitant 
increase in tumor growthr. As a result, PSA measurements, while extremely 
useful for identifying recurrence of many hormone insensitive tumors (25,26,29), 
fail to demonstrate the state of the prostate from the time of initiation of therapy to 
recurrence since the expression of PSA is effectively altered and may give false 
negative or positive results in some cases. If a marker could be identified which is 
not down-regulated following hormone ablation therapy, the steady state of the 
prostate could be monitored and recurrence may be identified following therapy at
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8a much earlier time which may offer an increased life expectancy for prostate 
carcinoma patients.
A recently discovered prostate associated biomarker designated the prostate 
specific membrane antigen (PSMA), recognized by the mouse monoclonal 
antibody (MAb) 7E11-C5, may have the properties to meet some or all of the 
needs described above. The murine MAb 7E11-C5 was produced against a crude 
membrane extract of the LNCaP prostate carcinoma cell line by Horoszewicz, et 
al. (83). Initial immunohistochemical analysis showed PSMA expression, as 
recognized by MAb 7E11-C5, to be highly restricted to normal, benign and 
malignant prostate epithelia and appeared to have an intracellular localization 
(83,84). Therefore, PSMA is similar to PSA in that it represents a potential novel 
prostate specific but not carcinoma specific marker. The nature of the antigen was 
initially identified to be a predominantly 100 kDa membrane associated 
glycoprotein (85-87). Recently, the cDNA for PSMA was cloned and the DNA 
and amino acid sequence were determined (88) which encodes a single 100 kDa 
transmembrane glycoprotein (89).
The initial biochemical characterization of the MAb 7E11-C5.3 epitope on 
PSMA demonstrated that it was susceptible to both periodate oxidation (90,91) and 
proteolytic digestion. Periodate cleaves vicinal hydroxyl groups on carbohydrate 
residues and thus, is used as a general assay for carbohydrate content in antigenic 
epitopes. These observations led to the initial conclusion that the epitope consisted 
of a glycopeptide (91,92). Lectins, which bind to specific carbohydrate residues 
were utilized in studies to block MAb 7E11-C5 binding to PSMA. These lectin 
blocking experiments indicated that the carbohydrate in the antigenic epitope 
consisted o f galactose residues. However, further studies which attempted to more 
specifically determine the type of carbohydrate present in the epitope were unable 
to detect any carbohydrate at all (92).
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9Two classes of carbohydrates found in glycoproteins are well characterized 
based on the linkage of the sugar to the peptide backbone. These classes are 0- 
linked and N-linked sugars which are linked to the free hydroxyl groups of serine 
and threonine residues and the free amino group of asparagine residues, 
respectively (93). As a result of the distinct differences between these two classes 
of linkages, it is relatively simple to distinguish the two by treatment of the antigen 
with sodium borohydride (94) which cleaves O-linked sugars or by incubating the 
cell line with tunicamycin (95) which inhibits the addition of the initial 
oligosaccharide to the neo-peptide. Neither of these treatments was able to 
abrogate 7E11-C5.3 binding which was confusing in light of the periodate 
sensitivity which suggested a carbohydrate was present as part o f  the epitope. 
Additionally, attempts to digest the antigen with a variety of glycosidases and 
blocking experiments with specific monomeric or polymeric carbohydrates and 
amino sugars were equally unable to inhibit 7E11-C5.3 binding. Since periodate 
oxidation is a highly accepted method for determining carbohydrate content in 
antigenic epitopes (96,97), these data added considerable confusion to the 
understanding of the biochemical nature of the antigen and its antigenic epitope. 
Several possibilities may explain the apparent conflict in these data: 1) The epitope 
may indeed contain a carbohydrate moiety which is neither O- nor N-linked in 
nature which would explain the failure of sodium borohydride and tunicamycin 
treatments to abrogate antibody binding; 2) the periodate treatment may affect a 
part of the epitope which is not a carbohydrate (i.e. the polypeptide backbone or 
some other post-translational modification); or 3) the specific carbohydrate in the 
epitope may be inaccessible or unaffected by the conditions normally utilized in 
the biochemical characterization assays.
Our understanding of the basic biology of PSMA and MAb 7E11-C5.3 is 
far behind the pursuit of approval from the Food and Drug Administration (FDA)
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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for use in clinical applications. Although the utility of this MAb for diagnosis and 
therapy has yet to be fully established, clinical trials using an  ^*1 Indium labeled 
conjugated form of MAb 7E11-C5.3 *In CYT-356) to localize metastatic 
prostate foci (98) and sites of prostatic carcinoma recurrence following radical 
prostatectomy (99,100) were found to be superior to traditional staging and 
imaging modalities. Phase I clinical trials have recently been initiated to evaluate 
the efficacy of 7E11-C5.3 radionuclide immunoconjugates for treating metastatic 
prostate cancer (Maguire, Cytogen Corporation, personal communication).
Another possible clinical application using RT-PCR to detect metastatic cells 
expressing PSMA mRNA in the whole blood of patients has recently been reported 
( 101, 102).
Since this monoclonal antibody or molecular probes for PSMA may be 
utilized for in vivo clinical assays, it is imperative that the prostate specific 
membrane antigen recognized by MAb 7E11-C5.3 be more fully characterized. 
Specifically, the subcellular localization of the antigen needs to be confirmed by 
an in depth study since an intracellular epitope may hinder the ability of CYT-356 
to localize a living tumor mass in vivo. Much of the biochemical studies o f PSMA 
have been previously reported although, as noted above, several contradictions 
need to be resolved including the question of whether the epitope contains a 
peptide, a glycopeptide or a carbohydrate moiety. The regulation of the expression 
of the PSMA gene also needs to be addressed to determine if the 
radioimmunoscintographic assays can be utilized with patients receiving endocrine 
therapy. Previous reports suggest that PSMA glycoprotein expression may 
increase following hormone ablation therapy (87) while PSMA mRNA levels may 
decrease in the presence of androgen hormones (89). Clinical protocols for 
diagnosis and therapy will be greatly affected by the results of these regulatory 
studies. If the PSMA gene is down-regulated by androgen ablation similar to PSA,
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then CYT-356 directed immunoscintigraphy and immunotherapy will have to be 
administered prior to hormone therapy. However, if the PSMA gene is not 
controlled by androgen hormones or is upregulated following ablation, both the 
diagnostic and therapeutic approaches can be done concomitant with endocrine 
therapy.
B. FOCUS OF THE PRESENT INVESTIGATION.
The objective of this study was to more fully understand the physical and 
biochemical nature of the PSMA glycoprotein recognized by the murine 
monoclonal antibody (MAb) 7E11-C5.3. The specific aims of this study were: (1) 
to determine the subcellular localization of PSMA; (2) to determine the 
biochemical and physical nature of the PSMA glycoprotein; and (3) to begin to 
understand the regulation of the PSMA gene.
1. To accomplish the first aim, the LNCaP cell line was analyzed by 
mechanical cellular subfractionation utilizing gradient density centrifugation and 
Western blot analysis to determine if PSMA is a cytoplasmic, nuclear or 
membrane glycoprotein. Light microscopy analysis utilizing multiple techniques 
including immunoperoxidase and immunofluorescence microscopy was 
undertaken to begin to determine the localization of PSMA within the cell. Then, 
immunoelectron microscopy of LNCaP cells was carried out to definitively 
determine the subcellular localization of PSMA.
2. The second aim was addressed by repeating previously reported 
experiments where necessary to confirm the initial observations. Once these 
results were verified, additional studies were carried out to explain the conflicting
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results garnered from this biochemical characterization. Specifically, the question 
of why MAb 7E11-C5.3 reactivity to PSMA was abrogated by periodate oxidation 
while assays to determine the specific carbohydrate failed to decrease activity. To 
address this question, the MAb 7E11-C5.3 antigenic epitope on PSMA was 
mapped with synthetic peptides. The reactive peptides were then treated with 
periodate as described for the analysis of the native antigen to determine if they 
were susceptible to oxidation which would lead to the false conclusion that the 
epitope contains a glycopeptide.
The characteristics of PSMA expression in prostate cell lines, prostate 
tissues and exocrine products of the prostate gland, as well as non-prostate tissues 
and human serum was thoroughly examined by Western blot analysis. The 
physical characteristics o f PSMA were also evaluated using polyacrylamide gel 
electrophoresis under differing conditions to determine the physical nature of the 
PSMA glycoprotein.
3. To begin to understand the regulation of the PSMA gene, a suitable 
model system had to be developed to study the expression of prostate specific 
genes. A model system was designed utilizing the PPC-1 primary prostate 
carcinoma cell line and which allowed for the control of both the level of androgen 
receptor expression and the concentration of androgen hormones in a prostate 
epithelial cell. The PSA promoter was cloned and utilized as a control for 
androgen upregulation in these experiments. In order to isolate the 5’ flanking 
DNA from the PSMA gene, PCR primers specific for the PSMA cDNA were used 
to amplified probes for the PSMA gene. These molecular probes were used to 
screen a human cDNA library to isolate the PSMA cDNA. A restriction fragment 
encompassing 700 bp of the 5' end of the cDNA was then used to probe a human 
genomic library and several PSMA genomic clones were identified. The genomic 
clones were mapped and sequenced, and a fragment containing approximately
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
13
1000 bp upstream of the translational start site was cloned into a basic 
chloramphenicol acetyl transferase (CAT) reporter gene construct containing no 
endogenous enhancers or promoters. The PSMA 5’ flanking DNA or the PSA 
control constructs were transiently transfected into the model system described 
above and assayed for CAT mRNA expression to definitively determine if PSMA 
was regulated by dihydroxytestosterone.
In summary, this work has provided important new information regarding 
the PSMA glycoprotein which will substantially impact ongoing clinical trials for 
in vivo imaging and therapeutic strategies. The biochemical nature of the MAb 
7E11-C5.3 epitope was deduced and mapped to the amino terminal end of the 
PSMA peptide backbone in the intracellular domain. PSMA was found to be 
expressed in normal, benign, and malignant prostate tissue, normal small intestine, 
salivary gland, and brain tissue and shed into the seminal fluid but not serum of 
males. The PSMA glycoprotein was shown to be a 100 kDa monomer under 
reducing and denaturing conditions and a second species of approximately 180 
kDa was observed under non-denaturing conditions which indicated PSMA may 
exist as a dimer or has considerable secondary and tertiary structure in its native 
state. The PSMA detected in tissue and seminal plasma was slightly larger (120 
kDa) indicating PSMA from LNCaP may be different in the level of post- 
translational modifications. Finally, a model system was devised to study the 
promoter of PSMA which was found to be quite different from the PSA promoter 
in that it was not inducible by androgen hormones.





1. POTENTIAL HAZARDS. Hazardous aspects of this study included the use 
of radioactive isotopes, toxic chemicals, potentially infected tissues, body fluids, 
and recombinant DNA molecules. All work with radioisotopes was carried out in 
designated laboratories approved with the oversight o f the Radiation Safety and 
Biohazards Institutional Committees. Absorbent bench covers, rubber gloves, lab 
coats, disposable plastic labware were used to prevent and/or contain 
contamination. Periodic swipe tests were carried out by the investigator as well as 
by the Radiation Safety Office as provided for in the laboratory licensing. Toxic, 
corrosive or carcinogenic chemicals were limited to the laboratories where the 
studies were being conducted. Fume hood, gloves, plastic face shield, and lab 
coats were used, and fire extinguishers and Spill-Packs were at hand at all times. 
Excess acids or bases were neutralized prior to disposal, and all waste chemicals 
were handled under the direction of the Environmental Safety Committee. 
Similarly, all human tissues and body fluids were handled with protective clothing, 
gloves and masks and/or as recommended by the Biosafety Committee. Disposal 
of these products was by autoclaving or incineration. Recombinant DNA 
experiments were conducted in a Biosafety Level 2+ laboratory in accordance with
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the NIH Guidelines for Research Involving Recombinant DNA Molecules and 
Institutional Biohazards Committee.
2. CELLS. LNCaP and PC3 cells were obtained from the American Type 
Culture Collection, DU 145 cells were kindly provided by Don Mickey (Duke 
University). The PPC-1 cell line was provided by Dr. Art Brothman (University of 
Utah) and the PPC-1 AR5 sub-line containing the androgen expression vector was 
provided by Dr. Michael McPhaul (University of Texas Southwestern Medical 
Center).
3. REAGENTS. Lectins were obtained from E.Y. Laboratories (San Mateo, 
CA). O-glycanase and N-glycanase enzymes were purchased from Genzyme 
(Boston, MA). Methyltrienalone (R1881) was purchased from New England 
Nuclear (Wilmington, DE), the pGEM7Zf+, pCAT basic vectors and the pGEM T 
cloning system were purchased from Promega (Madison, WI). Reagents for in 
vitro translation and RNAse protection assays were purchased from Ambion 
(Austin, TX). ED AC (l-ethyl-3-[3-dimethylaminopropyl] carbodiimide), OPD (0- 
Phenylenediamine dihydrochloride), all other enzymes, carbohydrates, 
carbohydrate conjugates and chemicals were purchased from Sigma Chemical 
Company (St. Louis, MO) unless otherwise noted.
4. MONOCLONAL AND POLYCLONAL ANTIBODIES. The monoclonal 
antibody 7E11-C5.3, purified by protein-A affinity chromatography from murine 
ascites, was provided by Cytogen Corporation (Princeton, NJ). The MAb 
concentration was determined using a single radial immunodiffusion system 
(TAGO, Burlingame, CA). Monoclonal antibodies OKT-9 (Ortho Immunology 
Systems, Raritan, NJ.), Hsp-70 (Sigma Immunochemicals, St. Louis, MO), PCNA
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(DAKO Corporation, Carpinteria, CA), and the ployclonal antiserum PG-21 
specific for the androgen receptor (Affinity Bioreagents, Neshanic Station, NJ.) 
were purchased and utilized according to the manufactures recommendations.
5. LNCAP XENOGRAFT TUMORS. Male athymic (nu/nu) Swiss background 
nude mice and Fox Chase SCID inbred mice (CB-17/ICrTac-scid DF), 4-6 weeks 
old (Taconic Farms, (Germantown, NY) were housed in sterilized cages with filter 
bonnets, and were given autoclaved laboratory rodent chow (Purina, St. Louis, 
MO) and filtered tap water ad libitum. Mice were given injections of 2.5 mg of 
cyclophosphamide i.p. one day prior to s.c. injections in the left rear flank with 1 x 
107 LNCaP cells in exponential growth phase, in 0.2 ml. of sterile medium or 
PBS. Subsequently, LNCaP tumors were propagated by s.c. implantation of tumor 
fragments aseptically transferred from donor to cyclophosphamide-treated, 
recipient mice. The same methods were used to grow LNCaP tumors in SCID 
mice, except SCID mice were not treated with cyclophosphamide.
6 . TISSUES AND SEMINAL PLASMA. All pathological tissue specimens 
were obtained from biopsy, surgery or autopsy materials which were removed only 
for appropriate diagnostic and therapeutic purposes. That which was not required 
for diagnosis and would normally be discarded was provided to this study. 
Similarly, samples of body fluids routinely taken for diagnosis or monitoring, no 
longer required for diagnosis, were also utilized. Since these tissues and body 
fluids were classified as discarded and the anonymity of the patient was 
maintained in all records and publications, such procurement qualified for NIH 
exemption number 4. Prostatic fluids were obtained by prostate massage and 
seminal plasma by masturbation from normal donors and patients with BPH, 
prostatitis, and active prostate adenocarcinoma. The purpose of the study, the
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amount and how the sample was collected and the risks and benefits were 
explained folly to the patient by the attending urologist. A signed and witnessed 
consent form was required prior to collection of the specimen. There was little to 
no risk associated with these procedures. The confidentiality of the patient was 
maintained by assigning code numbers to the specimens which were utilized on all 
report forms and publications. Patient files and history forms were kept in locked 
file cabinets.
Following collection, the semen samples were treated as previously 
described (103,104) with minor modifications. Briefly, the samples were frozen 
prior to liquefaction and stored at -70° C. until further analysis. The samples were 
thawed at room temperature by adding 1/2 volume dilution buffer (123mM NaCl,
5 mM KC1, 1 mM MgSCty, ImM EDTA, and 37 mM Tris pH 8.0). Pefablock 
(Boehringer Mannheim) was added to a final concentration of 0.1 mM and 50X 
protease inhibitor cocktail (0.28 mM Antipain; 0.75mM Pepstatin; 60mM EDTA) 
was added to a final concentration of IX. The samples were centrifuged for 5 min. 
at 25,000 x g to remove cells or cellular debris and the supernatants, termed 
seminal plasma, were transferred to eppendorf tubes and stored at -70°C.
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B. METHODS.
1. TISSUE CULTURE. All cells were grown in RPMI 1640 media 
supplemented with L-glutamine and 5% fetal calf serum (Gibco-BRL, 
Gaithersburg, MD) at 37° C and 5% carbon dioxide. The androgen expression 
plasmid was maintained in the PPC-1 AR5 sub-line with selective media 
supplemented with 400 pg/ml G418 (Life Technologies, Inc., Grand Island, NY). 
Stripped serum media was supplemented with pure Finasteride, kindly provided 
for this study by Merck and Co., (West Point, PA), a well characterized inhibitor 
of 5 alpha-reductase activity (105-108) at a concentration of 500 r|M/L for the 
hormone regulatory studies.
2. MECHANICAL SUBCELLULAR FRACTIONATION. The method 
employed here was modeled after several studies found in the literature (109-111). 
Briefly (see Fig. 1), cultured LNCaP cells were harvested and lysed in a hypotonic 
media (ImM NaHCO) then dounce homogenized with fifty up and down strokes.
It was imperative that the majority of the cells were lysed since the initial 
centrifugation steps would pellet out unbroken cells as well as nuclei. Therefore, 
the homogenization was monitored by trypan blue staining and the subsequent 
steps were not performed until >99% of the cells are lysed. The homogenate was 
centrifuged at 500 x g for 5 min. at 4°C and the pellet resuspended in buffer 
containing 16.0% sucrose then underlayed with 20 .0% sucrose and centrifuged in a 
swinging bucket rotor at 150,000 x g for 60 min. at 4°C. The nuclei (N) were 
pelleted to the bottom of the 20 .0% sucrose while other membrane components 
remained at the interface of the two layers. The supernatant was removed by
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FIGURE 1. Subcellular fractionation of LNCaP cells. The cells were fractioned 
into a nuclear fraction (N), heavy membrane fraction (HM), light membrane 
fraction (LM), and cytoplasmic fraction (C), utilizing a series of linear and 
gradient centrifugation steps as shown.
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aspiration and the nuclear pellet resuspended in 16.0% sucrose and centrifuged 
again to remove any residual membranes since it has been shown to be difficult to 
obtain totally pure nuclei (111). The supernatant from the 500 x g spin was 
centrifuged at 10,000 x g for 15 minutes at 4°C. The pellet from this step 
represented the heavy membrane fraction (HM) containing predominately the 
rough endoplasmic reticulum, the Golgi apparatus and mitochondria. The 
supernatant was centrifuged at 150,000 x g for 60 minutes at 4°C. The pellet from 
this step was the light membrane fraction (LM) containing smooth endoplasmic 
reticulum, plasma membrane and any vesicular membranes while the supernatant 
represented the soluble cytoplasmic fraction (C).
The fractions obtained from this fractionation method were analyzed by 
Western blot and ELISA for the presence of PSMA. Control antibodies were used 
as markers for mitochondria (MU213 specific for HSP70 found in mitochondria), 
plasma membrane (OKT-9, specific for the transferrin receptor) and nucleus (a 
PCNA antibody specific for PCNA) were utilized to verify that the partitioning 
was efficient.
3. LIVING LNCAP IMMUNOFLUORESCENCE STAINING. LNCaP cells 
were grown to approximately 50% confluency on collagen coated chambered 
slides (Nunc, Naperville, IL.). The media was removed by aspiration and the cells 
were washed twice with PBS (136 mM NaCl, 1.7 mM KC1, 8 mM Na2HP0 4 , 1.5, 
mM KH2PO4 , 0.9 mM CaCl2 , 0.5 mM MgCl2, pH 7.4) warmed to 37° C. 
Blocking serum (10% goat serum in PBS) was added to the chambers and 
incubated at room temperature for 1 hr. then removed by aspiration. The primary 
antibody (7E11-C5.3 at 20pg/ml, OKT-9 at 15 pg/ml, PSA-5 at 1 jig/ml; or IgGl 
isotype matched control at 10 pg/ml) was added to the cells and incubated at room 
temperature in a humid chamber for 1 hr. The cells were washed twice with PBS
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followed by the addition of secondary antibody (fluorescein isothiocyanate [FITC] 
labeled goat F(ab') a  mouse antibody with Evan’s blue counter stain, Baxter 
Healthcare Corporation, West Sacramento, CA) and incubated at room 
temperature for 1 hr. The cells were washed twice with PBS then visualized with a 
fluorescence microscope.
4. FIXED LNCAP CELL IMMUNOFLUORESCENCE STAINING. LNCaP 
cells were grown to approximately 50% confluency on chambered slides as 
described above. The cells were fixed for 20 min. in 10% buffered formalin and 
rinsed twice with PBS. The cells were permeabilized briefly in 0.1% Triton-XlOO 
in PBS for 5 min., washed twice with PBS, then stained as described above using 
7E11-C5.3; OKT-9; PSA-5; and the IgG isotype matched negative control 
antibody.
5. IMMUNOPEROXIDASE STAINING. The immunoperoxidase staining was 
carried out exactly as described above for the fixed immunofluorescence staining 
except the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) was 
used with a peroxidase labeled horse a  mouse antibody. The positive staining was 
visualized by the addition of a color substrate (diaminobenzidine [DAB]) for 10 
min., then rinsed twice with PBS and counter stained with Mayer’s Hematoxylin 
for 5 min.
6. IMMUNOELECTRON MICROSCOPY. To definitively determine the 
localization of the PSMA glycoprotein, a method for immunoelectron microscopy 
of PSMA was designed from previously reported studies in the literature (112-120) 
which were utilized with 7E11-C5.3 and IgGl isotype matched control antibodies. 
LNCaP cells were grown to confluency on plastic coverslips. The coverslips were
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
22
fixed in half strength Kamovsky's fixative (2% paraformaldehyde and 1% 
glutaraldehyde in cacodylate buffer) for 30 minutes then osmicated in osmium 
tetroxide following standard conditions. The coverslips were embedded in LR- 
White and polymerized overnight at 4°C. Ultrathin sections were cut with a glass 
knife and mounted on nickel EM grids. The grids were stained using the hanging 
drop method by suspension on drops of blocking buffer ( 10% goat serum in 
filtered PBS) for 1 hr. then primary antibody for up to 48 hours, rinsed by repeated 
hanging drop incubations in wash buffer, then incubated with a secondary goat anti 
mouse immunoglobulin antibody labeled with a 10 r]m gold bead. Following 
several rinses, the grids were counterstained by placement at the bottom of a drop 
of filtered uranyl acetate for 15 minutes in the dark then rinsed 3 times by dipping 
20 times for each wash in fresh sterile water. After the final rinse the grids were 
placed at the bottom of a drop of lead citrate and stained for 15 seconds then rinsed 
3 times as described above. The grids were air dried on filter paper then analyzed 
on a JEOL transmission electron microscope.
7. SERUM STARVATION-STIMULATION. LNCaP cells were grown to 
approximately 50% confluency on chambered slides as described above. The cells 
were washed three times with PBS warmed to 37°, serum free RPMI 1640 media 
was added to each well and the slides were incubated for an additional 48 hr. at 
37° C. Following serum starvation, the serum free media was removed by 
aspiration and replaced with RPMI 1640 media supplemented with 5% calf serum 
and incubated at 37°C. Slides were removed at time points (0 min.; 15 min.; 30 
min.; 60 min.; 2 hr.; 4 hr.; 6 hr.; 8 hr.; 10 hr.; 24 hr.; and 48 hr.) following serum 
starvation and fixed for 20 min. in 10% buffered formalin and stored in PBS at 4°
C. After all of the time points were collected and fixed the cells were 
permeabilized briefly in 0.1% Triton-XlOO in PBS for 5 min. then washed twice
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with PBS. Immunofluorescence staining was carried out as described above using 
MAb 7E11-C5.3 and an IgGl isotype matched control antibody.
8 . MITOCHONDRIAL PURIFICATION. Mitochondria were purified from 
LNCaP cells following a previously reported procedure (121). Six 162 cm2 tissue 
culture flasks were seeded with LNCaP cells and grown to confluency. The cells 
were harvested then pelleted by centrifugation. The cell pellet was resuspended in 
6 ml IX Mitochondrial Isolation Buffer (MIB) (0.25 M sucrose, 40 mM Tris pH 
7.0,0.1 mM EDTA) then dounce homogenized on ice with 40 up and down 
strokes. The homogenized material was centrifuged in a Beckman JA20 rotor at 
2,000 x g for 30 min. at 4°C the supernatant collected and centrifuged at 8,500 x g 
for 35 min. at 4° C. The supernatant from this step was discarded and the pellet 
resuspended in 6 ml IX MIB and centrifuged again at 8,500 x g for 35 min. The 
supernatant was discarded and the pellet resuspended in 6 ml IX MIB and dounce 
homogenized. This suspension represented the crude mitochondrial fraction. The 
crude mitochondrial fraction was applied to a two-step sucrose gradient composed 
of 10 ml of 25% sucrose in TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0) and 
13 ml of 42.5% sucrose in TE buffer and centrifuged at 26,000 x g for 75 min. at 4 
0 C. The percentage of sucrose in each solution was confirmed by a refractive 
index of 1.3775 and 1.4035 respectively. The mitochondria were collected at the 
interface of the two sucrose layers and diluted in 2 volumes TE buffer and applied 
to a second sucrose gradient purification. The mitochondria were again collected 
at the interface of the two sucrose layers, diluted in 2 volumes TE buffer then 
centrifuged at 22,000 x g for 20 min. at 4° C. The pellet from this step, 
representing the purified mitochondria was resuspended in 2 volumes PBS and 
stored at -20° C until needed.
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9. MEMBRANE PREPARATIONS. LNCaP cells were harvested and pelleted 
by centrifugation at 1,000 x g. The pellet was washed once with ice cold 
phosphate buffered saline (136 mM NaCl, 1.7 mM KC1, 8 mM Na2HPC>4 , 1.5, 
mM KH2PO4 , 0.9 mM CaCl2 , 0.5 mM MgCl2 , pH 7.4) and pelleted again. The 
pellet was resuspended in hypotonic buffer (ImM NaHC0 3 ) containing a protease 
inhibitor cocktail (0.28 mM Antipain; 0.75mM Pepstatin; 60mM EDTA) and 
incubated on ice for 30 min. then dounce homogenized. The homogenate was 
centrifuged at 2,000 x g for 5 minutes in a Beckman JA20 rotor to pellet whole 
cells and nuclei. The supernatant was collected and centrifuged at 138,000 X g for 
2 hours. The supernatant was discarded and the pellet, representing a crude 
membrane preparation, was resuspended in PBS and stored at -70° C.
10. PSMA AFFINITY COLUMN PURIFICATION. Membrane preparations 
were resuspended in solubilization buffer (30 mMTris pH 7.5, 0.5M NaCl, 1% NP- 
40, 0.5% DOC, 0.1% SDS, 0.5 mM DTT) and protease inhibitor cocktail (as 
described above) and incubated for 2 hr. at 4° C. on a rotator. The solubilized 
material was centrifuged at 100,000 x g for 1 hr. at 4° C. to pellet non-solubilized 
material. The supernatant was collected, diluted 1:2 with 20 mM Tris pH 8.0 and 
loaded onto an Affinica Protein A-7E11-C5 affinity column constructed using the 
manufacturers instructions (Schleicher & Schuell, Keene, NH). The column was 
washed with wash buffer (20 mM Tris pH 8.0, 0.1% NP-40,0.1 mM DTT) and 
eluted with 2N NH4OH, pH 11.0. The eluted fraction was placed in 3500 mw cut 
off dialysis tubing (Spectrum, Houston, TX) and dialyzed against 20 mM Tris 
HCL pH 4.0 containing 0.1 mM DTT for 2 hr. at 4° C. The eluant was then 
concentrated against polyethylene glycol compound (MW 15,000-20,000) to 
approximately 500 pL. Protein concentrations were estimated using the BCA 
protein assay following the manufacturers instructions (Pierce, Rockford IL).
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11. SDS-PAGE PURIFICATION OF PSMA. Affinity column purified PSMA 
was loaded into the lanes of an SDS-PAGE mini-gel at 30 pg/Iane. One lane of 
purified PSMA and one molecular weight marker lane were stained with coomasie 
blue. The remaining PSMA bands were excised using the stained lane as a guide 
and placed in dialysis tubing (12-14,000 mw cut-off; Spectrum, Houston, TX) 
containing 500 pi CAPS buffer (10 mM CAPS pH 11.0; 0.5 mM DTT) and 
electroeluted for 2 hr. at 12 mAmps in CAPS buffer. The acrylamide bands were 
removed from the dialysis tubing and the eluted protein was dialyzed against 
distilled deionized water for 2 hr. then removed from the dialysis tubing and dried 
in a Savant speed-vac concentrator.
12. PHYSICAL AND BIOCHEMICAL TREATMENT. Purified PSMA from 
crude LNCaP membrane preparations was boiled for 10 min. in the presence or 
absence of mercaptoethanol or SDS. Periodate oxidation (122) and sodium 
borohydride (123) treatments were carried out as previously described. Briefly, 
for the periodate oxidation, the antigen was incubated in 50 mM sodium acetate 
(pH 4.5) containing 5 mM sodium periodate for 1 hr. at room temperature in the 
dark. The reaction was quenched by the addition of 0.1 M glycine for 30 min. For 
the sodium borohydride treatments, the antigen was incubated in 0.1 M NaOH 
containing 2.0 M NaBH4 at room temperature for 16 hr. The reaction was 
quenched by the addition of 0.5 pi glacial acetic acid. The treated samples were 
then analyzed by RIA or western blot analysis. Proteolytic digestion was carried 
out by incubating the purified PSMA at 37°C for 24 hr. using 100 pi of the 
following protease solutions: trypsin type III (1,10, and 100 U/ml); alpha 
chymotrypsin type VII (5, 50, and 500 mU/ml); Protease type XXI (2,20, and 200 
mU/ml); and Protease type XXVI (8, 80, and 800 mU/ml). The treated PSMA 
was then analyzed using a modified RIA assay or western blot analysis.
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13. GLYCOSIDASE TREATMENT. Purified PSMA was treated with Beta- 
galactosidase, fiicosidase, endo F, and chondroitinase ABC in Eppendorf tubes 
following methods previously described (19-21). For the N-glycanase digestion 
the antigen was boiled for 3 min. in the presence of 0.5% SDS and 0.1M 
mercaptoethanol then diluted in PBS containing 10 mM phenanthroline and NP- 
40. The N-glycanase (Genzyme, Boston, MA: 0.3 mU) was added and the 
reaction incubated overnight at 37°C. For the O-glycanase digestion, the antigen 
was first denatured in SDS and mercaptoethanol as for the N-glycanase treatment 
then digested with neuraminidase for 2 hr. O-glycanase (0.5 mU) was added and 
the reaction mixture incubated overnight at 37°C.
14. MODIFIED RADIOIMMUNOASSAY (RIA). The wells of a microtiter 
plate were rinsed with distilled water. The antigen was added at a concentration of 
3 pg/well and dried overnight at 37° C then fixed with 0.1% gluteraldehyde for 5 
min. at room temperature. The wells were rinsed twice with PBS and non-specific 
binding sites were blocked with 10% goat serum for 30 min. at room temperature. 
The blocking serum was removed by aspiration and 25 |il of the primary antibody 
was added to each well and incubated for 1 hr. at room temperature. Each well 
was rinsed 3 times with PBS followed by the addition of 100,000 counts/well of a
125I radiolabelled goat anti mouse secondary antibody and incubated for 1 hr. at 
room temperature. The wells were rinsed 4 times and each well counted on a 
gamma counter and reported as counts per minute (CPM).
15. COMPETITIVE BINDING EXPERIMENTS. The carbohydrate 
concentrations were adjusted to 0.05 M with PBS. The 7E11-C5.3 MAb was 
incubated with the carbohydrate or PBS control for 2 hours at room temperature. 
Fifty ul of the mixture was then used as the primary antibody for an RIA using
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
27
purified PSMA from LNCaP membrane extract as the antigen. For lectin 
competitive binding studies, lectins were used at a concentration of 1 mg/ml in 
PBS. The lectins or PBS control were added to antigen coated wells in a volume 
of 100 pi and incubated for 2 hours at room temperature. The wells were washed 
3 times with PBS and an RIA assay was performed as described above. Data for 
both the carbohydrate and lectin experiments were expressed as a percentage of the 
control binding using the following formula:
CPM of treated well 
% control binding=______________________ X 100
CPM of PBS control well
16. TUNICAMYCIN TREATMENT. LNCaP cells were cultured in the 
presence of tunicamycin for 7 days as previously described (124) at Cytogen 
Corporation (Princeton, NJ.) and supplied for this study. The cells were harvested 
and membrane preparations were prepared as described above.
17. PEPTIDE SYNTHESIS. Peptides were synthesized on a Synergy Peptide 
Synthesizer using F-MOC chemistry (Perkin Elmer-Applied Biosystems, Foster 
City, CA). Following synthesis the peptides were cleaved from the column matrix 
by removing the entire resin from the column into a 50 ml polypropylene 
centrifuge tube then 50 pi thioanisole, 50 pi 1,2, ethanedithiol (EDT), and 900 pi 
trifluoroacetic acid (TFA) were added in a fume hood. This slurry was incubated 
at room temperature with shaking for one hour. Following cleavage, the peptides 
were extracted three times in 15 mis of t-butyl methyl ether (MTBE) decanting the 
ether from the peptide-resin pellet after centrifugation at 1,000 RPM for 5 min. 
Following the final extraction the peptide-resin pellet was resuspended in 10 ml 
sterile water or 30% acetonitrile in water for hydrophobic peptides then passed
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through a pasteur pipette in which a plug of glass wool had been inserted. This 
procedure separated the extracted peptide from the synthesis resin. The peptide 
was aliquoted into eppendorf tubes and dried in a Savant speed-vac overnight. The 
peptides were stored in the dried form at -20° C. until needed then resuspended in 
sterile water for use.
18. HPLC ANALYSIS OF SYNTHETIC PEPTIDES. Synthetic peptides were 
separated on a C18 reversed phase HPLC column (Waters Delta-Pak C18; 300A, 5 
pm, 3.9x150 mm) using a Waters 650 HPLC system to test for purity. The column 
was equilibrated for 10 column volumes of 90% buffer A (HPLC water, 0.1% 
TFA) and 10% buffer B (80% acetonitrile in HPLC water, 0.09% TFA) and the 
baseline monitored at a wavelength of 214 qm at a flow rate of 0.2 ml/min. The 
percentage of TFA was titrated in both buffers such that they gave a constant 
baseline at a wavelength of 214 r|m. A small aliquot of the peptide was diluted in 
20 pi HPLC water and injected onto the column. The column was rinsed of 
unbound material for 5 min. at the initial buffer conditions then the percentage of 
buffer B was increased to 40% in a linear manner over a 50 min. time span 
followed by an increase to 90% buffer B in 5 min. to remove any tightly bound 
material then to 10% over a 10 min. period. Peptides were judged to be pure if > 
80% of the peptide was contained in a single peak.
19. DIRECT BINDING PEPTIDE ASSAY. Peptides were bound to wells of 
microtiter plates using the procedure previously described (125) with several 
modifications. Briefly, lOOpl of BSA (1 pg/ml) was dispensed into each well of a 
high binding EIA plate (Costar, Cambridge, MA) and dried overnight. The plates 
were rinsed twice with PBS followed by two rinses with distilled water. Various 
concentrations of peptides were added to the wells in a volume of 50 pi followed
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by 50 jj.1 o f ED AC crosslinker (10 mg/ml) or water control and the plates 
incubated overnight at 4°C with shaking. The plates were washed 5 times with 
wash buffer (PBS containing 0.05% Tween-20). The concentration of peptides 
adhered to the plate was determined by protein assay of the peptide-EDAC mixture 
prior to and following the crosslinking incubations. A standard ELISA assay was 
then performed (as described below).
20. COMPETITIVE BINDING PEPTIDE ASSAY. Competition plates were 
made by first dispensing 100 pi BSA (1 pg/ml) into the wells of a high binding 
El A plate and dried overnight. The plate was rinsed twice with PBS and twice 
with distilled water prior to the addition of peptides. Serial 1:5 dilutions of each 
peptide were made with water starting at a concentration of ImM with a final 
volume of 40 pi in each well. The antibody concentration utilized was determined 
by finding the concentration o f MAb 7E11-C5.3 which gave half maximal binding 
to a constant concentration of purified PSMA antigen at 200 rig per well 
determined to be 1 pg/ml. Forty pi of MAb 7E11-C5.3 (1 pg/ml) was added to 
each well and the plate was incubated at 4°C overnight with shaking.
Antigen plates were prepared by dispensing lOOpl of purified PSMA (2.0 p 
g/ml) into the wells of a high binding EIA plate (Costar, Cambridge, MA) and 
incubating overnight at 4°C with shaking. The antigen plates were washed 4 times 
with wash buffer and blocked with blocking buffer (1% BSA in PBS containing 
0.05% Tween-20) for 1 hr. at room temperature. The blocking buffer was 
removed and the 80 pi of the peptide-antibody mixture from the inhibition plates 
prepared above were transferred to the antigen plates and utilized as the primary 
antibody for a standard ELISA assay.
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21. STANDARD ELISA ASSAY. Microtiter plates, activated with peptide or 
antigen, were blocked for 1 hr. at room temperature with blocking buffer (1% BSA 
in PBS containing 0.05% Tween-20) and shaking. The blocking buffer was 
removed and MAb 7E11-C5.3 or competition mix (as described above) was added 
to each well and incubated for 2 hr. at room temperature with shaking. The plates 
were washed 5 times in wash buffer with the final wash being removed by vacuum 
aspiration to ensure all of the wash buffer was removed. The secondary antibody 
(1 pg/ml, horseradish peroxidase labeled, horse anti-mouse antibody, Vector 
laboratories, Burlingame,Ca) was added at 50 pi per well and incubated for 2 hr. at 
room temperature with shaking. The plates were washed 5 times with wash buffer 
and all of the buffer was removed with the final washr. Following the final wash, 
200 pi of OPD substrate was added to each well and incubated for 5 to 30 min. 
with shaking and read at 405 rim on an EL-340 Microplate reader (Bio-Tek 
Instruments, Winooski, VT).
22. DETERMINATION OF AFFINITY CONSTANT (Ka). The affinity of 
MAb 7E11-C5.3 for the native antigen and peptides was determined by a 
modification of a method described previously (126). MAb binding was plotted as 
bound/free antibody as a function of the concentration of bound antibody (M).
The regression coefficient (Ka) was calculated according to the method of 
Scatchard (127) and student’s t test was applied to determine the significance of 
the results.
23. PSMA ELISA ASSAY. The PSMA ELISA assay was performed by 
incubating 100 pi each sample (diluted to 20 pg/ml) per well of high binding-flat 
bottom ELISA plates (Costar Corporation) overnight at 4° C with shaking. The 
plates were washed with wash buffer (PBS containing 0.05% Tween-20) three
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times followed by two washes with distilled water. Nonspecific binding sites in 
the wells were blocked by incubating 100 pi blocking buffer (PBS containing 2% 
BSA and 0.05% Tween-20) in each well for two hours at room temperature with 
shaking. The blocking buffer was aspirated from the wells and the primary 
antibody added directly without washing in a volume of 100 pi per well and 
incubated at room temperature for 2 hr. The plates were washed as above and 100 
pi of the secondary antibody (Vector Laboratories, horse a  mouse 
immunoglobulin-horseradish peroxidase conjugate: 1:5000) was added and 
incubated for 2 hr. at room temperature followed by washing as above. The color 
substrate (o-phenylenediamine dihydrochloride, Sigma Chemical Company) was 
added at 200 pi per well and the absorbance read on a micro-plate reader (Bio-Tek 
Instruments) at 405 nm at intervals of 5, 10,15, and 30 minutes.
24. WESTERN BLOT ANALYSIS. Western blot analysis for PSMA was 
carried out on the individual samples by loading equal protein concentrations into 
the lanes of 4-20% gradient SDS-PAGE gels and running under reducing and 
denaturing conditions (128) then electrophetically blotted to Immobilon-P 
membranes (Millipore, Bedford, MA). The membranes were incubated for 1 hr. at 
37°C in blocking buffer (5X Denhardt's buffer, IX BBS, 0.1% NP-40, 1.5% BSA). 
The blocking buffer was removed and the membranes incubated with MAb 7E11- 
C5.3 (20pg/ml) for 1 hr. at room temperature. The primary antibody was removed 
and the membranes washed for 10 min. x 3 with wash buffer (30 mMTris pH 7.5, 
0.5M NaCl, 1% NP-40,0.5% DOC, 0.1% SDS, 0.5 mM DTT) followed by the 
secondary antibody incubation ( horse anti-mouse horseradish peroxidase labeled 
secondary antibody diluted in blocking buffer at a dilution of 1:10,000; Vector 
Laboratories, Burlingame, CA.) for 1 hr. at room temperature. The secondary 
antibody was removed and the membranes were washed for 10 min. x 3 in wash
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buffer. The blots were developed using the ECL method (Amersham Life 
Sciences, Arlington Heights, IL) according to the manufacturers instructions and 
exposed to X-ray film. Apparent molecular weights were calculated on multiple 
blots using known molecular weight markers.
25. COMPETITIVE INHIBITION WESTERN BLOT ANALYSIS. The
competitive blocking studies were carried out identically to the Western blot 
experiments described above except the PSMA active peptide N1.19 was added in 
a 20 fold molar excess over the MAb 7E11-C5.3 during the primary antibody 
incubation.
26. TWO DIMENSIONAL (2-D) GEL ELECTROPHORESIS. 2-D
experiments were done using the Investigator 2-D Electrophoresis System 
(Millipore, Marlborough, MA) following the manufacturers directions. Briefly, 10 
pg of affinity purified antigen was loaded on top of a preparative isoelectric 
focusing tube gel and overlaid with sample overlay buffer. The tubes were 
electrophoresed for 17 hours at 1000 volts followed by 15 min. at 1500 volts. The 
gels were extruded onto pre-cast 4-20% gradient SDS-PAGE gels and layered with 
a 1% agarose sticker containing 0.1% Bromphenol blue. The second dimension 
was run at 16 mAmps overnight. The gel was removed from the apparatus and 
blotted to Immobilon-P (Millipore, Bedford, MA) for Western blot analysis. 
Isoelectric points were estimated by determining the pH gradient o f a tube gel, run 
at the same time as the sample, which contained only ampholytes. The analytical 
tube gel was cut into 1 cm sections, incubated in 3 ml double distilled water for 2 
hr. followed by pH measurement.
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27. ANALYSIS OF PSMA IN SERUM. Serum samples from informed and 
consented normal donors were collected. Serum from patients with BPH or CaP 
were obtained from the tissue bank o f the Virginia Prostate Center, Eastern 
Virginia Medical School. Four separate pools of serum were prepared using 
samples from 5 non-pregnant normal females, 5 normal males under the age of 
forty, 5 BPH patients, and 5 patients with stage D2 CaP were pooled. Twenty pg 
o f affinity purified PSMA was used to spike 500 pi of the stage D2 pooled serum 
and incubated for 12 h at 37°C. An additional 500 pi aliquot of the same Stage D2 
pooled serum representing 29.09 mg of total protein was incubated in 
solubilization buffer (as described above) for 2 h at 4°C and applied to a 7E11- 
C5.3 affinity column and eluted and prepared as described above for PSMA 
purification. Twenty five pg of membrane preparations from LNCaP cells and 
normal prostate tissue; 100 pg of a normal seminal plasma; 400 pg of the spiked 
D2 serum; 20 pg of affinity purified stage D2 serum; and 400 pg of non-spiked D2 
serum, BPH serum, normal male serum, and normal female serum were loaded 
into the lanes of two identical 4-20% SDS-PAGE gels, electrophoresed, 
transferred to Immobilon-P membranes and developed for Western blot analysis as 
described above with either 7E11-C5.3 or an isotype matched (IgG j) control 
antibody.
28. ISOLATION OF GENOMIC DNA FROM LNCAP CELLS. Three 162 
cm2 tissue culture flasks were seeded with LNCaP cells and grown to confluency. 
The cells were washed twice with TBS (30 mM Tris, 150 mM NaCl pH 7.3) then 
removed by scraping using a rubber policeman into a volume of 0.5 ml TBS and 
collected in ependorf microcentrifiige tubes. The cells were pelleted at 2000 RPM 
in a benchtop microcentrifuge for 10 min. at 4°C, resuspended in 1 ml ice cold 
TBS and pelleted again. The pellet was resuspended in 4 ml TE buffer (pH 8.0)
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followed by 40 ml extraction buffer (10 mM Tris pH 8.0,0.1 M EDTA, 20 pg/ml 
RNAse A, 0.5% SDS) and incubated at 37°C. for 1 hr. Proteinase K was added to 
a final concentration of 100 pg/ml and incubated at 50°C for 3 hr. then cooled to 
room temperature. An equal volume of TE saturated phenol was added to the tube, 
mixed gently, then centrifuged at 5000 x g for 15 min. at room temperature. The 
aqueous phase was removed and extracted two more times with phenol. Following 
the third phenol extraction, 0.2 volumes of 10 M ammonium acetate was added 
followed by 2 volumes of ethanol at room temperature. The DNA was pelleted at 
5000 x g for 5 min. at room temperature, washed with 70% ethanol, air dried then 
resuspended in sterile water.
29. CLONING OF THE PSA PROMOTER. All plasmid constructs were 
prepared using standard methods (129). The 5' flanking DNA fragment of the 
PSA gene was obtained by PCR amplification of 100 ng of genomic DNA from 
the LNCaP cell line using oligonucleotide primers derived from the published 
sequence of the PSA gene (130-132). The sequences for these primers were:
PSA1 5'-CATTGTTTGCTGCTGCACGTTGGAT-3' and PSA2 5'-TCCGGG 
TGCAGGTGGTA AGCTTGG-3'. The oligonucleotides were synthesized in the 
Core Molecular Biology laboratory at Eastern Virginia Medical School and 
purified by HPLC chromatography as described below. The PCR reaction mixture 
(with final concentrations of 200 pM dNTP; 500r)M primers; 100 rig LNCaP 
genomic DNA; 2 mM MgCl2; IX PCR reaction buffer) was prepared on ice in a 
final volume of 99 pi without Taq polymerase, overlayed with 50 pi mineral oil 
then placed into the wells of a thermo cycler (Perkin Elmer). The PCR reaction 
conditions for the amplification o f the PSA promoter were as follows: 5 min. 
initial denaturation at 94° C; 1 pi Taq polymerase (2.5 U/pl) was added to each 
reaction mixture following the denaturation and gently mixed; 30 cycles of: 45
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sec denaturation at 94° C; 1 min. annealing at 61° C; and 1 min. extension at 72° 
C; a final extension of 6 min. at 72° C was carried out following cycling to 
ensure that all products were full length and the PCR fragments were purified by 
HPLC chromatography as described below. The peaks were collected by hand and 
the DNA precipitated with 2 volumes ice cold ethanol at -70 C for 1 hr, 
centrifuged at 14,000 RPM at 4 C then washed with 70% ice cold ethanol then 
resuspended in sterile water. The purified PCR products were subcloned into the 
pGemT vector (Promega) following the manufactures protocol. Positive clones 
were sequenced by double stranded automated DNA sequencing using the 
dideoxynucleotide chain termination method to verify the cloning of the proper 
DNA fragment.
30. HPLC PURIFICATION OF SYNTHETIC OLIGONUCLEOTIDES. The
synthetic oligonucleotides were cleaved from the synthetic resin in 1.5 ml 
ammonium hydroxide at room temperature for 1 hr then placed in a screw top tube 
at 55° C for 5 hr. The cleaved oligonucleotides were dried in a Savant speed-vac 
overnight and stored at -20° C. until needed. A C18 reversed phase column 
(Waters Delta-Pak C18; 300A, 5pm, 3.9x150 mm) was equilibrated with 100% 
buffer A (100 mM Triethylammonium Acetate pH 7.0) and 0% buffer B (100 mM 
Triethylammonium Acetate pH 7.0,70% acetonitrile) at 0.8 ml/min. and the 
baseline monitored at a wavelength of 260 Tim. The oligonucleotides were 
resuspended in 40 pi HPLC grade water then loaded onto the column. A gradient 
was run from 0% buffer B to 40% buffer B over 40 min. ramped to 100% Buffer B 
in 5 min. then to 0% buffer B in 5 min. The predominant peak was collected by 
hand and dried in a Savant speed-vac and stored at -20° C until needed.
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31. DNA SEQUENCE ANALYSIS. The DNA dideoxy chain termination 
sequencing analysis was performed using an ALF DNA Sequencer (Pharmacia, 
Upppsala, Sweden) using the manufacturers procedures. In brief, 5 pg DNA was 
denatured with 8 pi 2N NaOH in a final volume of 40 pi at room temperature.
7 pi 3M sodium acetate, 4 pi water and 120 pi cold 100% ethanol were added then 
incubated in a dry ice/ethanol bath for 15 min. The DNA was precipitated by 
centrifugation at 14,000 RPM for 15 min. at 4°C then washed with 70% cold 
ethanol. The pellets were air dried then resuspended in 10 pi water. 10 pmoles of 
fluorescein labeled primer (T7 Universal or Reverse primers) and 2 pi annealing 
buffer were added to the DNA and incubated at 65°C for 5 min., moved to 37°C 
for 10 min. then room temperature for 10 min. 3 pi dimethylsulfoxide (DMSO), 1 
pi extension buffer, and 2 pi T7 DNA polymerase (4U/pl) was added to the DNA 
mixture and 4.5 pi o f this solution was added to 2.5 pi of A,C,G,T mixes 
prewarmed to 37°C and incubated at 37°C for 5 min. The reactions were stopped 
by adding 5 pi stop buffer and samples stored at -20°C until needed. 6 pi of each 
sample was separated on a denaturing polyacrylamide gel and analyzed by 
fluorescence analysis.
32. CLONING OF THE PSA PROMOTER INTO A BASIC CAT VECTOR.
A pGemT clone which contained the PSA promoter (PSA3) was digested with Sph 
I and Pst I at 37° C for 3 hr. The restriction fragments were purified by anion 
exchange chromatography and the peak containing the 600 bp promoter fragment 
was precipitated and air dried. The pellet was resuspended in sterile water and 
stored at -20° C until needed. The PSA promoter fragment was directionally 
cloned into the Pst I and Sph I sites of the pCAT basic vector (Promega) which 
contains no promoter or enhancer sequences.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
37
33. CLONING OF THE PSMA CDNA. A DNA probe for the PSMA cDNA 
was obtained by PCR amplification o f a single stranded cDNA population 
synthesized from LNCaP poly-a RNA. The sequences for these primers were: 5’- 
ATGTTGCCTCTCTCTCTCGC TCGG-3’ and 5 ’-TTGCCTTCAAAGCCTTC 
ATCAGGG-3 ’. These primers amplify an approximately 1,700 bp fragment of the 
PSMA cDNA between +37 and +1733 of the published cDNA sequence. The 
PCR amplification of the PSMA cDNA fragment was carried as described for the 
PSA promoter except the annealing temperature was 50° C. The PCR fragments 
were purified and cloned into the pGemT vector as described above and positive 
clones were verified by sequence analysis. The insert from one clone was purified 
and labeled with digoxygenin (Boehringer Mannheim, Mannheim, Germany) 
following the manufactures protocol. This labeled probe was used to screen a 
lambda phage cDNA library made from the LNCaP cell line.
34. LIBRARY SCREENING. Lambda phage were plated on LB agar plates at a 
density of 10,000 PFU/plate and grown overnight at 37°C or until near confluency. 
The plates were incubated at 4°C. for at least 1 hour or overnight to cool the agar. 
Nylon membranes were numbered and placed on top of the plates for 2 min. and 
holes were poked through the membrane and agar in an asymmetric fashion with a 
needle. The membranes were removed from the plates and immediately denatured 
plaque side up on filter paper saturated with denaturing buffer (1.5 M NaCl, 0.5 M 
NaOH) for 2 min. then transferred to neutralization buffer (1.5 M NaCl, 1M Tris 
pH 8.0) for 5 min. followed by rinse solution (0.2 M Tris pH 7.5, 0.3 M NaCl, 30 
mM sodium citrate) for 30 sec. The membranes were dried on 3mm paper plaque 
side up, UV crosslinked at 150 mJoule and stored dry until needed. The 
membranes were prehybridized in a shaking water bath at 65°C in prehybridization 
buffer (5X SSC, 1% blocking buffer, 0.1% N-lauroylsarcosine, 0.02% SDS) for 2
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hr. The prehybridization buffer was removed and the diluted and boiled probed 
(15 rig/ml) was added and incubated overnight in a shaking water bath at 65°C. 
Following the overnight incubation the hybridization solution was removed and 
saved for reuse at a later time. The membranes were washed twice for 5 min. in 
2X wash buffer (2X SSC containing 0.1% SDS) at room temperature with shaking 
then twice for 15 min. in 0.5X wash buffer (0.5X SSC containing 0.1% SDS) at 65 
°C.
The membranes were incubated in blocking buffer (2% casein, 100 mM 
Tris, 150 mM NaCl pH 7.5) for 30 min. at room temperature then an a  digoxigenin 
antibody labeled with alkaline phosphatase was added at a dilution of 1:5,000 and 
incubated for 1 hr. The membranes were washed 3 times for 10 min. each in wash 
buffer (100 mM Tris, 150 mM NaCl pH 7.5) then the alkaline phosphatase enzyme 
was activated with activation buffer (100 mM Tris pH 9.5, 100 mM NaCl, 50 mM 
MgCl2) for 2 min. The activation buffer was removed and 2 ml of color substrate 
(3.37 mg/ml nitroblue tetrazolium salt, 1.75 mg/ml 5-bromo-4-chloro-3-indolyl 
phosphate) was added to each membrane and incubated in the dark for 5-30 min. 
Positive plaques were isolated by taking a core of the agar plate and isolating 
lambda phage in SM buffer containing 1 drop of chloroform. A secondary and 
tertiary screening was carried out on these isolated phage to ensure that a 
homogeneous lambda phage population was isolated.
35. CLONING OF THE PSMA 5’ FLANKING DNA. A restriction fragment 
from the 5' end of the PSMA cDNA (700 bp) was isolated by digesting the 
PSMA1 cDNA clone with Hpa I followed by gel purification of the 750 bp 
fragment. The 750 bp fragment was labeled with digoxigenin as described above 
and used to screen a human genomic library made from a Sau II partial digestion 
of placental genomic DNA (Clonetech Laboratories Inc., Palo Alto, CA). The
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isolated genomic clones were characterized by restriction mapping and southern 
blot analysis using both the original PSMA probe or the oligonucliotide primer 
which corresponds to the very 5' end of the cDNA. By following this method, 
clones which had a high probability of containing the 5' flanking regions were 
identified. Fragments which hybridized to the probe were subcloned into a 
pGem7Z+ vector (Promega) and sequenced by the dideoxy-chain termination 
method.
36. PREPARATION OF COMPETENT CELLS FOR 
ELECTROPORATION. A glycerol stock culture of the E. coli strain JM109 
was inoculated into 5 ml LB broth and grown overnight at 37° C. The overnight 
culture was added to 1 L of fresh LB broth and incubated until the OD600 was 
between 0.5 and 1.0. The cells were chilled on ice for 30 min. then transferred to 
four sterile 250 ml centrifuge bottles and centrifuged at 3,000 RPM at 4° C for 20 
min. The supernatant was decanted and the pellets were resuspended in 10 ml cold 
sterile water then diluted to 250 ml and centrifuged again at 3,000 RPM at 4° C for 
20 min. The supernatant was decanted and the cells were resuspended as above 
then 2 bottles were combined, diluted to 250 ml and centrifuged again. Following 
this final centrifugation the pellets were resuspended in 10 ml cold sterile 10% 
glycerol in a 50 ml centrifuge tube and centrifuged again. The pellet was 
resuspended in 3 ml cold sterile 10% glycerol and snap frozen in 80 pi aliquots in 
a dry ice/ethanol bath and stored at -70° C.
37. SOUTHERN BLOT ANALYSIS. The DNA was electrophoresed in a 0.8% 
agarose gel in TBE buffer and visualized by ethidium bromide staining. The gel 
was rinsed in water for 15 min. at room temperature with shaking then soaked in
0.25M HCL for 15 min. at room temperature followed by 60 min. in denaturing
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buffer (1.5 M NaCl, 0.5 M NaOH) then 60 min. in neutralizing buffer (1 M Tris 
pH 8.0; 1.5 M NaCl). The gel was rinsed in 20X SSC (3 M NaCl, 300 mM sodium 
citrate, pH 7.0) and transferred using 20 X SSC overnight to positively charged 
nitrocellulose membranes under the pressure of weights. Following Southern 
transfer, the membranes were air dried and the DNA fixed by UV crosslinking at 
150 mJoule and stored in air tight containers at room temperature until needed.
38. HYBRIDIZATION OF SOUTHERN TRANSFERS. Southern transfer 
membranes were prehybridized in a shaking water bath at 65 °C in prehybridization 
buffer (5X SSC, 1% blocking buffer, 0.1% N-lauroylsarcosine, 0.02% SDS) for 2 
hr. The prehybridization buffer was removed and the diluted and boiled probe (10 
r|g/ml) added then incubated in a shaking water bath at 65°C overnight. Following 
hybridization, the hybridization solution was removed and the membranes were 
washed twice for 5 min. each in 2X wash buffer (2X SSC containing 0.1% SDS) at 
room temperature with shaking then twice for 15 min. each in 0.5X wash buffer 
(0.5X SSC containing 0.1% SDS) at 65°C.
The membranes were incubated in blocking buffer (2% casein, 100 mM 
Tris, 150 mM NaCl pH 7.5) for 30 min. at room temperature then an adigoxigenin 
antibody labeled with alkaline phosphatase was added at a dilution of 1:5,000 and 
incubated for 1 hr. The membranes were washed for 10 min. 3 times in wash 
buffer (100 mM Tris, 150 mM NaCl pH 7.5) then the alkaline phosphatase enzyme 
was activated with activation buffer (100 mM Tris pH 9.5, 100 mM NaCl, 50 mM 
MgC12) for 2 min. The activation buffer was removed and approximately 2 ml of 
lumiphos reagent (Boeringer Mannheim) was added to the membranes for 1 min. 
The membranes were placed between two sheets of acetate film and loaded into an 
X-Ray film cassette. X-Ray film was placed on the membrane in a dark room and 
exposed for various lengths of time then developed in an automatic film developer.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
41
39. STRIPPING OF STEROID HORMONES FROM CALF SERUM.
Steroid hormones were removed from fetal calf serum utilizing previously 
published methods (133,134). Briefly, the serum used to supplement the media 
was stripped by incubation with activated charcoal and dextran at 55°C for one 
hour with stirring. This stripping was repeated several times to ensure the removal 
of the steroid hormones. The serum was filter sterilized and hormone levels 
assayed at the endocrinology laboratory located in the Howard and Georgianna 
Jones Institute for Reproductive Medicine
40. TRANSIENT TRANSFECTIONS. The method utilized here is an 
adaptation o f methods previously reported (135,136). Either the parental PPC-1 
cells or the PPC-1 AR5 cell line containing the androgen receptor expression 
plasmid were seeded into 100 mm plates and grown for 48 hrs in RPM I1640 
supplemented with 5% calf serum. The media was removed by aspiration and the 
cells were washed twice with Tris buffered saline (TBS) (30 mM Tris, 150 mM 
NaCl pH 7.3) warmed to 37° C. For each transfection to be performed, 5 pg of the 
promoter-CAT construct DNA was mixed with 1 ml TBS and DEAE dextran (50 
pg/ml). One ml of this mixture was added to the plate and incubated for 30 min. at 
37° C with occasional rocking then overlayed with 10 ml RPMI 1640 containing 
100 pm chloroquine phosphate and incubated for 3 hr at 37° C. The media was 
removed by aspiration and the plates washed twice with 5 ml Tris buffered saline 
at 37° C then overlayed with RPMI 1640 supplemented with 5% stripped serum or 
5% stripped serum plus 1 nM methyltrienalone (R1881). After 48 Hr, the cells 
were collected by scraping with a rubber policeman pelleted by centrifugation and 
stored at -70° C until needed. All treatments were prepared in triplicate.
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41. RNA EXTRACTION. Cells collected following transient transfections were 
lysed in 2 ml lysis buffer (10 mM EDTA pH 8.0, 0.5% SDS) then extracted with 4 
ml phenol and centrifuged at 5,000 RPM for 10 min. at 4° C. The aqueous phase 
was transferred to a fresh tube containing 440 pi cold 30 mM Tris-Cl (pH 8.0) and 
180 pi 5M NaCl. Two volumes of ice cold ethanol was added and incubated at - 
70°C for 1 hr. then centrifuged at 5,000 RPM for 10 min. at 4° C and air dried.
The RNA was redissolved in 200 pi ice cold TE buffer and transferred to a 
microcentrifiige tube and precipitated with 4 pi 5M NaCl and 500 pi ice cold 
ethanol followed by centrifugation at 12,000 x g for 5 min. at 4°C in a 
microcentrifuge. The ethanol was removed, the pellets air dried then resuspended 
in 30 pi sterile water.
42. CHLORAMPHENICOL ACETYLTRANSFERASE (CAT) RNASE 
PROTECTION ASSAY. A high specific activity ribonuclease probe for the CAT 
gene was made by in vitro transcription of a linearized CAT plasmid using the 
MAXIscript kit (Ambion Inc., Austin, TX) in the presence of [a-32P] UTP, 800 
Ci/mmol followed by gel purification to eliminate prematurely terminated 
transcription products. For each sample, 1 X 10s cpm of the labeled probe was 
added to 50 pg of total RNA and ethanol precipitated with 2 volumes ice cold 
ethanol and ammonium hydroxide to 0.5 M for 15 min. at -70°C. The RNA was 
pelleted at 14,000 RPM at 4°C and resuspended in hybridization buffer and 
vortexed. The tubes were incubated at 90°C for 4 min. then vortexed and 
centrifuged briefly and hybridized overnight at 45 °C. RNAse digestion buffer was 
then added to the tubes and incubated at 37°C for 30 min. then precipitated for 1 hr 
at -70°C, pelleted and stored at -20°C until needed. The digested fragments were 
boiled for 4 min. then separated on a denaturing polyacrylamide gel and visualized 
with a Phospholmager (Molecular Dynamics).




A. DETERMINATION OF THE SUBCELLULAR LOCALIZATION OF 
TH E PROSTATE SPECIFIC MEMBRANE ANTIGEN
1. LNCaP CELLULAR SUBFRACTIONATION. One method of 
determining the relative subcellular localization of a molecule of interest is to 
separate cells into different components and analyze the fractions. In the present 
study, a subcellular subfractionation was carried out on cultured LNCaP cells to 
give a rough estimate of the localization of PSMA. Utilizing a series of linear and 
sucrose gradient centrifugation steps, LNCaP cells were separated into four 
fractions including the nuclear fraction (N); the heavy membrane fraction (HM) 
containing predominantly the rough endoplasmic reticulum and mitochondria; the 
light membrane fraction (LM) composed of the plasma membrane, smooth 
endoplasmic reticulum, and small vesicular membranes; and the cytoplasmic 
fraction (C) containing the soluble cytoplasmic components. To ensure that this 
mechanical fractionation efficiently separated the cellular components, a panel of 
control antibodies was utilized to monitor the efficiency of the fractionation. 
Figure 2 demonstrates that the mitochondrial HSP70 heat shock protein 
(recognized by MAb MU213) was segregated into the HM fraction while the 
transferrin receptor was only detected in the LM component. The prostate specific
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antigen (PSA) was detected in the LM fraction with a small amount being detected 
in the nuclear fraction and the proliferative cell nuclear antigen (PCNA) was 
detected only in the nucleus. None of the markers utilized were found in the 
cytoplasmic fraction. These data suggest that the fractionation was efficient except 
for some contamination of the nuclear fraction which has been reported by many 
investigators.
The PSMA glycoprotein was detected in both the HM and the LM fractions 
(Fig. 2) indicating that two pools of this molecule exist in LNCaP cells. A small 
amount of reactivity was also seen in the nuclear fraction, but this may be 
contamination. Western blot analysis of these fractions using MAb 7E11-C5.3 
was also carried out to verify the results garnered from the RIA assay as well as to 
determine if  the PSMA found in the LM and HM fractions was similar in 
molecular size. Figure 3 shows that the majority of the PSMA was found in the 
HM and LM fractions by Western blot analysis and that the PSMA in both 
fractions was at approximately 100 kDa; however, the HM fraction also contained 
a higher molecular weight band which was barely detectable in the LM fraction.
2. DETERMINATION OF THE LOCALIZATION OF PSMA BY 
LIGHT MICROSCOPY. In order to determine if the MAb 7E11-C5.3 antigenic 
epitope on PSMA was intracellular or extracellular, LNCaP cells were grown on 
tissue culture slides then stained without fixation or permeabilization prior to 
immunofluorescence staining with MAb 7E11-C5.3 or a control antibody (OKT-9) 
specific for the extracellular domain of the transferrin receptor. The hypothesis for 
this experiment was that monoclonal antibodies would not be able to cross a living 
cell membrane. As a result, if the epitope was localized inside the cell there would 
be no staining, whereas an extracellular epitope would result in a ringed staining 
around the circumference of the cell. The transferrin receptor antibody was able to















FIGURE 2. Control RIA assay to determine the efficiency of the 
cellular subfractionation. The transferrin receptor (OKT-9) was 
detected predominantly in the light membrane (LM) fraction, 
PCNA was detected only in the nuclear fraction (N), the 
mitochondrial Hsp70 (MU213) was detected in the heavy 
membrane fraction (HM), and PSA was detected in the LM and the 
N fractions. PSMA was detected in both the HM and LM fractions 
indicating that two pools of this molecule exist in LNCaP cells.
The data represents the average of 3 independent expeiments ± SE.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
46
FIGURE 3. Western blot analysis of cellular fractions.
The majority of the PSMA was found in the light membrane 
(LM) and heavy membrane (HM) fractions with very little 
in the nuclear (N) and cytoplsmic (C) fractions.
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bind its epitope on the extracellular face of the LNCaP cells resulting in a ring of 
staining around the cells (Fig. 4 panel A) as expected for an extracellular epitope. 
On the other hand, MAb 7E11-C5.3 was unable to bind to its epitope (Fig. 4 panel 
B) indicating its epitope was intracellular.
To more definitively determine the localization of PSMA within LNCaP, 
cells were grown on tissue culture slides to approximately 50% confluency then 
fixed with buffered formalin and permeabilized briefly in a weak detergent 
solution prior to staining. This permeabilization step was carried out to assure the 
antibody probes could cross the plasma membrane and stain any intracellular 
antigens. The fixed and permeabilized LNCaP cells were stained with antibodies 
specific for PSA (PSA-5), the transferrin receptor(OKT-9), or an isotype matched 
(IgGl) control antibody which does not react with human prostate cells as controls 
for intracellular, plasma membrane, and negative staining respectively. The FITC 
labeled secondary antibody utilized in this study was diluted in a buffer containing 
Evan’s blue which acts as a counter stain and allows the entire cell to be visualized 
under ultraviolet light by a red fluorescence. The isotype matched control 
antibody did not stain the LNCaP cells (Fig. 5, panel A) and all that was visible 
was the red counter staining of the Evan’s blue. Note the ability to differentiate 
the nucleus from the cytoplasm of the cells by the red fluorescence of the Evan’s 
blue. Staining with PSA-5 showed a remarkable vesicular staining of the LNCaP 
cells (Fig. 5, panel B) suggesting a localization in secretory vesicles. As expected, 
the transferrin receptor appeared to be predominantly localized to the plasma 
membrane (Fig. 5, panel C) as demonstrated by the circumscription of the cell by 
the yellow fluorescence. The staining for PSMA with MAb 7E11-C5.3 however, 
appeared to be cytoplasmic and not localized at the plasma membrane or the 
nucleus (Fig. 5, panel D). There was no circumscription of the cells as seen with 
the transferrin receptor and no vesicular staining similar to PSA.
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FIGURE 4. LNCaP cells were grown on tissue culture slides 
to approximately 50% confluency. The slides were rinsed with 
PBS and stained for immunofluorescent microscopy without 
fixation or permeabilization. (A) Positive staining of LNCaP cells 
with the OKT-9 antibody specific for an extracellular domain on 
the transferrin receptor. (B) LNCaP cells stained with MAb 7E11-C5.3 
with no positive signal indicating that the MAb 7E11-C5.3 epitope 
is intracellular.












FIGURE 5. Light microscopy of fixed LNCaP cells grown on cultured 
slides. The FITC labelled secondary antibody was diluted in Evans’ blue 
which results in a red fluorescent counter staining of the cells. The cells were 
stained with an IgGl isotype matched control (A), PSA-5 (B), OKT-9 
specific for the transferrin receptor (C), and 7E11-C5.3. The isotype matched 
control was negative while PSA-5 gave a very vesicular staining. OKT-9 
staining was typical of membrane proteins in that the staining was in a form 
of a ring around the cells. 7E11-C5.3 staining appeared to be predominantly 
cytoplasmic and not localized to the nucleus or solely to the plasma membrane.
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A similar set of experiments was carried out using immunoperoxidase 
staining methods and visible light microscopy with identical results. The staining 
pattern for PSMA was observed to be cytoplasmic at low power (fig 6 , panel A) 
and was more evident at 100 X (Fig. 6, panel B).
3. IMMUNOELECTRON MICROSCOPY OF LNCaP CELLS. A
series of immunoelectron microscopy studies was then performed to definitively 
determine the intracellular localization of PSMA within the cytoplasm of LNCaP 
cells. The first set o f experiments utilized a chromagen (DAB) to visualize PSMA 
staining. This method was similar to the standard immunoperoxidase staining 
shown above except it was done at the electron microscopic level where the 
deposits o f DAB were visualized as electron dense particles. Figure 7 shows the 
positive staining of MAb 7E11-C5.3 at the cytoplasmic face of the cell membrane 
(CM) and microvilli (MV) (panels B and C) and within several mitochondria (M) 
(panel B and E). The isotype matched negative control antibody exhibited no 
staining at the cell membrane or mitochondria (Fig. 7, panels A and D).
The DAB staining methods can be reletively non-specific at the electron 
microscopy level. Therefore, to more precisely demonstrate the localization of 
PSMA, a secondary monoclonal antibody directly labeled with a 10 nm gold bead 
was used in place of chromagen staining. Immunogold staining with MAb 7E11- 
C5.3 also resulted in positive staining with a concentration of gold beads at the 
cytoplasmic face of the CM (see arrows) and near a gap junction (GJ) between two 
LNCaP cells (Fig. 8, panel A) and concentrated in and around mitochondria (panel 
B).
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FIGURE 6. LNCaP cells were grown in a monolayer on 
tissue culture slides. The cells were fixed and stained with 
7E11-C5.3 using a horseradish peroxidase method and 
visualized with DAB and counter stained with Mayer’s 
hematoxalin. Positive cytoplasmic staining is evident at 
40X (A) and is obvious at 100X (B).
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FIGURE 7. Immunoelectronmicroscopy utilizing DAB staining.
(A) The IgGl control showed negative staining at the cell membrane at
36.000 X. (B) Arrows pointing to positive 7E11-C5.3 staining at the cell 
membrane (CM) and within mitochondria (M) at 28,000 X. (C) Arrows 
pointing to positive 7E11-C5.3 staining at the CM and microcilli (MV) and 
mitochondria at 81,000 X. (D) IgGl control negative staining of M at
81.000 X. (E) Positive 7E11-C5.3 staining of mitochondria at 13,000 X.
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FIGURE 8. Immunoelectron microscopy of LNCaP cells. The 
grids were stained with 7E11-C5.3 followed by a secondary antibody 
labelled with a 10 nm gold bead. (A) A cluster of gold beads at the 
inner face of the cell membrane (CM) and near a gap junction (GJ) 
between two LNCaP cells at 97,000 X. (B) Gold beads clustered in 
and around a mitochondria (M) at 97,000 X.
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4. MITOCHONDRIAL PURIFICATION. Since two separate 
experiments suggested that PSMA was, in part, localized to the mitochondria of 
LNCaP cells, mitochondria were purified from whole cell lysates and analyzed for 
the presence of PSMA. Based on the immunolocalization experiments, 
mitochondria purified from LNCaP cells would be expected to contain the PSMA 
glycoprotein. In fact, the 100 kDa PSMA glycoprotein was present in the LNCaP 
lysate (Fig. 9, lane 1), crude mitochondrial preparation (Fig. 9, lane 2) and purified 
mitochondria following several sucrose gradient centrifugation steps (Fig. 9 lane 
3) adding further evidence that PSMA is associated with the mitochondria of 
LNCaP cells.
5. EFFECTS OF SERUM STARVATION AND STIMULATION ON 
PSMA LOCALIZATION. LNCaP cells were grown to approximately 50% 
confluency on tissue culture slides. The normal media was removed and replaced 
with serum free media and the cells were serum starved at 37° C for 48 hours. The 
serum free media was then replaced with normal media and slides were collected 
at time points ranging from 0 to 48 hours after serum stimulation and the cells 
analyzed for PSMA by immunofluorescence microscopy as described above. The 
typical cytoplasmic staining pattern of PSMA was observed in all time points with 
little variation following serum stimulation suggesting that the localization of 
PSMA was not dependent on extracellular signals (data not shown).







m & r • .•
4 ' /
l^ s lill
;V..f ;; - • _ .. ,. '.. ••' • r:.-
ymmM
.. ' ; ' ii, r-fc.*'-. .■
V  •: V. *'?. ^  . :
FIGURE 9. Western blot analysis of crude and purified 
mitochondria. The mitochondria were purified by a series of 
centrifugation steps and sucrose gradient centrifugation. The 
LNCaP cell lysate contained a significant amount of the 100 kDa 
PSMA glycoprotein (lane 1) as did the crude mitochondrial 
preparation (lane 2) and pure mitochondria following two 
sucrose gradient centrifugation purifications (lane 3) indicating 
that PSMA is found in the mitochondria of LNCaP cells.
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B. BIOCHEMICAL CHARACTERIZATION OF THE 7E11-C5.3 EPITOPE 
ON THE PROSTATE SPECIFIC MEMBRANE ANTIGEN.
1. BASIC BIOCHEMICAL CHARACTERIZATION OF THE PSMA 
EPITOPE. The initial characterization of the MAb 7E11-C5.3 epitope on PSMA 
previously reported (92) utilized standard physical and biochemical techniques on 
purified material. These experiments were repeated here as a result of the apparent 
conflicts in the data as discussed in the Review of the Literature. However, the 
present study confirmed the previous results. The MAb 7E11-C5.3 epitope was 
stable after incubations at 100°C and after reduction or denaturation in 
mercaptoethanol and SDS (Fig. 10). The epitope was susceptible to oxidation of 
viccinyl hydroxyl groups by periodic acid suggesting a carbohydrate component of 
the epitope, although sodium borohydride and tunicamycin treatments (data not 
shown) were unable to inhibit binding. The increased binding of MAb 7E11-C5.3 
to PSMA following sodium borohydride treatment most likely results from the 
release of 0-linked carbohydrates which may mask the antigenic determinant.
Since the periodate and buffers utilized above were relatively harsh 
reagents, there was a possibility it was the ability of PSMA to adhere to the plastic 
wells of the RIA plate which was being affected and not the antigenic epitope on 
PSMA. To control for this possibility, untreated LNCaP lysate (Fig. 10B, lane 1), 
LNCaP lysate treated in water (lane 2), LNCaP lysate treated in acetate buffer 
(lane 3), and LNCaP lysate treated with acetate buffer and periodate (lane 4) were 
analyzed by immunoblot analysis. This experiment clearly demonstrates the 
7E11-C5.3 epitope on PSMA is destroyed by the periodate treatment alone.
The recognition of the PSMA epitope by MAb 7E11-C5.3 under reducing 
and denaturing conditions indicated the integrity of the epitope was not dependent
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Heat NaBH Periodate SDS 2Me
FIGURE 10. Basic biochemical analysis of the MAb 7E11-C5.3 epitope.
A) Purified PSMA from LNCaP cells was treated with heat (boiling for 10 min.), 
sodium borohydride (NaBH), periodate, sodium dodecyl sulfate (SDS), and 
beta mercaptoethanol (2Me). The antigenic epitope was recognized in a 
denatured and reduced form and was susceptible to periodate oxidation but 
not sodium borohydride treatment. B) Western blot analysis of PSMA 
without treatment (lane 1), treated for 1 hr in the dark with 50 ul of water (lane 2),
50 pi acetate buffer (lane 3), and periodate in acetate buffer (lane 4). The 
periodate treatment alone and not the acetate buffer is affecting the MAb 
7E11-C5.3 epitope on the PSMA glycoprotein. The bar graph represents the 
average of 3 independent experiments +/- SE.
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on secondary or tertiary structure of the native molecule. In order to determine if 
the primary amino acid chain was important in the epitope, the PSMA 
glycoprotein was treated with a variety of proteases having differing specificities. 
These digestions revealed the epitope to be highly susceptible to proteolysis (Fig.
11) indicating the epitope was dependent on an intact peptide backbone.
2. CARBOHYDRATE ANALYSIS. The periodate oxidation of the 
7E11-C5.3 epitope argued that a carbohydrate played a significant role in 
antigenicity. To determine which carbohydrates were present in the antigenic 
epitope, lectin competitive inhibition studies were carried out. These experiments 
demonstrated SB A, PNA and MPA lectins (Fig. 12), which are specific for D- 
galactose in either a monomeric form or a polymeric form, were able to reduce 
MAb 7E11-C5.3 binding while lectins which bound to other carbohydrates such as 
mannose, glucose, fucose, neuraminic acid, and N-acetyl-glucosamine had no 
effect (Fig. 12). To prove the specificity of these lectin experiments, PSMA was 
digested with both general and specific glycosidases prior to analysis by RIA using 
7E11-C5. Neither O-glycosidase nor N-glycosidase, used to cleave O-linked and 
N-linked oligosaccharides, respectively were able to reduce MAb 7E11-C5.3 
binding (Fig. 13). Digestion with specific enzymes, in particular P-galactosidase, 
also did not inhibit antibody binding (Fig. 13). Similarly, MAb 7E11-C5.3 binding 
was not inhibited in competitive blocking experiments using specific 
carbohydrates or aminosugars (Fig. 14). In particular, D-galactose (D-gal) and N- 
acetyl galactosamine (galNAc) were unable to inhibit binding in spite of the fact 
that lectins specific for these sugars (SBA, PNA, and MPA) were able to abrogate 
MAb 7E11-C5.3 binding. The surprising inability of these glycosidases and 
sugars
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FIGURE 11. Proteolytic digestion of PSMA. Purified PSMA was 
subjected to proteolytic digestion with a variety of proteases with 
different amino acid specificities. The PSMA from LNCaP cells was 
highly susceptible to trypsin (U/ml), chymotrypsin (mU/ml), 
protease type XXI (mU/ml), and protease type XXVI (mU/ml). The 
data represent the average of 3 independent experiments +/- SE.
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FIGURE 12. Competitive lectin binding analysis. Purified 
PSMA was incubated with the indicated lectins prior to 
a standard RIA assay to attempt to block the antigenic epitope 
of 7E11-C5.3. The lectin specificities are as follows: LPA 
(NeuNAc, D-galNAc, and D-GlcNAc), PHA (oligosaccharides), 
UEA (L-fuc), WGA (D-glcNAc, NeuNAc), GSII (D-glcNAc), 
ConA (D-man, D-glc), SBA (D-galNAc, D-gal), PNA (D-gal-B- 
(l-3)-D-galNAc), and MPA (D-gal). Lectins with a specificity 
for galactose residues were able to partially block the 
MAb 7E11-C5.3 epitope. The data represents the average of 3 
independent experiments +/- SE.
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FIGURE 13. Digestion of PSMA carbohydrates with glycosidases.
Purified PSMA was digested with neuraminidase (NM), beta-galactosidase 
(B-Gal), fucosidase (Fuc), O-glycanase (O-Gly), N-glycanase (N-Gly), Endo F, 
and chondroitinase ABC (Chon). None of the enzymes used were able to inhibit 
MAb 7E11-C5.3 binding which was surprising in light of the results from the 
lectin binding experiments. The data represents the average of 3 independent 
experiments +/- SE.
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FIGURE 14. Competitive blocking of the MAb 7E11-C5.3 epitope with specific 
carbohydrates. The MAb 7E11-C5.3 was incubated with the indicated carbohydrates 
in an attempt to block reactivity to purified PSMA. None of the specific carbohydrates 
or amino sugars were able to block the activity. Specifically, monomeric 
D-galactose and polymers of D-galactose (D-raffinose and gal-galNAc) were not 
able to compete although the lectin studies indicated a galactose component of 
PSMA was important in the antigenic epitope. The data represents the average 
of 3 independent experiments +/- SE.
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to abrogate binding indicates the lectin competitive inhibition may have been non­
specific.
3. DETERMINATION OF ACTIVE PSMA PEPTIDES. The amino 
acid sequence of PSMA has been previously reported (88) .  Computer modeling 
of this sequence (Fig. 15) indicates that there is a 19 amino acid intracellular 
domain followed by a 23 amino acid type II transmembrane domain while the 
remainder of the PSMA glycoprotein is extracellular. Since the 
immunolocalization experiments described above suggested the 7E11-C5.3 epitope 
on PSMA epitope was intracellular, several synthetic peptides were synthesized 
which corresponded to the 19 amino acids of the proposed intracellular domain of 
PSMA. Peptide N1.19 consisted of the entire 19 amino acid intracellular domain 
(MWNLLHETDSAVATARRPR) while peptides N1.6 (MWNLLH), N7.12 
(ETDSAV), and N13.19 (ATARRPR) were synthesized to effectively separate this 
domain into three segments. The synthetic peptides utilized for this study were 
sufficiently pure as judged by the fact that all peptides gave a single predominant 
peak when analyzed by reverse phase chromatography on a Waters 650 HPLC 
system (Fig. 16). The N1.19 and the amino terminal N1.6 peptide were recognized 
by MAb 7E11-C5.3 in a dose dependent manner although N1.6 had approximately 
30% less activity than N 1.19 while N7.12,N13.19 andN669 (MFLERA), a 
negative control peptide, were inactive (Fig. 17). The fact that these peptides were 
recognized by MAb 7E11-C5.3 indicated that the PSMA antigenic epitope was 
predominately composed of the core peptide structure and was indeed located at 
the amino terminal end of the glycoprotein.
4. PSMA PEPTIDE EPITOPE MAPPING. To further characterize the 
peptide portion of the PSMA epitope, the intracellular domain was completely
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FIGURE 15. Molecular domains of the proposed PSMA molecule. The cytoplasmic 
domain is made up of the first nineteen amino terminal amino acids; A transmembrane 
domain is localized at amino acids 20-43; the remaining portion of the molecule is 
extracellular. A limited degree of homology (54%) to the transferrin receptor (TR) is 
located at amino acids 417-567.
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FIGURE 16. A representative HPLC analysis of the PSMA 
synthetic peptides. The peptides were separated on a reverse 
phase column with an acetonitrile gradient and monitored at a 
wavelength of 214 rim. All of the PSMA peptides showed a single 
predominant peak with very little contamination.
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FIGURE 17. Direct binding PSMA peptide assay with 50 |al of each molar 
concentration of peptide. Peptides were bound to EIA plates with BSA and ED AC 
chemical crosslinker and used for a standard ELISA assay with MAb 7E11-C5.3. The 
concentration of MAb 7E11-C5.3 used (lpg/ml) was analytically determined from the half 
maximal binding to the purified antigen. Peptides N1.19 ( ■ )  and N1.6 (A)were active 
in a dose dependent manner while peptides N7.12 (• ) , N13-19 (A), and the control 
peptide N669 (O) were negative. The data represents the average of 3 independent 
experiments + SE.
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mapped with synthetic peptides. Table 1 shows the orientation of the synthetic 
peptides from the amino terminal end of the PSMA amino acid sequence 
beginning with the complete N 1.19 intracellular reactive peptide. Equimolar 
concentrations of each peptide were assayed in a direct binding assay in which the 
small PSMA peptides were first conjugated to BSA adsorbed to an ELISA plate 
using the chemical crosslinker l-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDAC). Baseline activity due to BSA and EDAC was measured in wells 
containing no peptide (Fig. 18 lanes 1-3). Peptides containing the first seven
Table 1. Amino acid sequences of synthetic PSMA peptides
Namea N- Amino Acid Sequence -C
N 1.19 M W N L L H E T D S A V A T A R R P R
N 1.12 M W N  L L H  E T D S A V
N l . 1 1 M W N L L H E T D S A
N 1 .1 0 M W N L L H E T D S
N1.9 M W N  L L H  E T D
N1.8 M W N  L L H  E T
N 1 .7 M W N L L H E
N1.6 M W N  L L H
N1.5 M W N L L
N 1.4 M W N L
N2.6 W N  L L H
N 7.12 E T D S A V
N 1 3 .1 9 A T  A R R P R
NAl .6 C W N  L L H
N1.6A M W N L L Y
N 3 4 4 M H I H S T
N 4 7 0 M Y S L V H
N 5 8 3 M V F E L A
N 6 6 4 M N D Q L M
N 6 6 9 M F L E R A
aPeptides named according to the distance from the amino terminal end of the PSMA 
amino acid sequence, amino acids: (M) methionine, (W) tryptophan, (N) asparagine, (L) 
leucine, (H) histidine, (E) glutamic acid, (T) threonine, (D) aspartic acid, (S) serine, (A) 
alanine, (V) valine, (R) arginine, (P) proline.
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FIGURE 18. PSMA peptide mapping using 50 pi of each peptide at a concentration of 
1 pmol/L. Baseline levels were defined by control wells containing only BSA 
or l-ethyl-3-[3-dimethylaminopropyl]carbodiimide (EDAC), or both. All peptides 
containing at least the first seven amino acids were equally active, with N 1.6 
activity dropping by approximately one third. The methionine-containing negative 
control peptide (N669) was below baseline, as were several additional peptides 
from the PSMA extracellular domain which have a similar motif to N1.6. The data 
represents the average of 3 independent experiments +/- SE.
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N-terminal amino acids had equal activity while N1.6 retained approximately two 
thirds the activity and N1.5 was below baseline levels (Fig. 18) indicating that the 
minimal reactive peptide was a 6mer composed of the first six amino terminal 
amino acids (MWNLLH), although the glutamic acid (E) at position 7 must also 
contribute to the epitope structure or stability of the epitope since there was a 
decrease in reactivity between the 6mer and 7mer peptides.
An intracellular epitope would seem to hinder the ability of MAb 7E11- 
C5.3 to image tumors in vivo. Therefore, several additional peptides within the 
extracellular domain of the proposed PSMA sequence which had a similar amino 
acid motif to N1.6 including N344, N470, N583, and N664 were synthesized and 
tested for MAb 7E11-C5.3 reactivity. None of these peptides were recognized 
(Fig. 18) indicating that there is only one MAb 7E11-C5.3 antigenic epitope on 
PSMA.
To demonstrate the specificity of the synthetic peptides and to utilize an 
alternative method which did not require binding of these small polypeptide 
molecules to microtiter plates, an indirect assay was utilized to competitively block 
MAb 7E11-C5.3 binding to LNCaP cell lysates. Peptides N1.19 and N1.6 were 
able to inhibit binding of MAb 7E11-C5.3 to PSMA in a dose dependent manner 
while control peptides and additional peptides present in the PSMA sequence were 
unable compete for MAb binding (Fig. 19).
5. AFFINITY OF MAb 7E11-C5.3 FOR PSMA AND PSMA 
PEPTIDES. The affinity o f MAb 7E11-C5.3 was determined for the native 
PSMA glycoprotein and the N1.19 and N1.6 active peptides. The affinity for the 
native PSMA glycoprotein (Ka 1.16 x 1 0 ^  M"^) was approximately 6.8 fold 
higher than the affinity for the N 1.19 peptide (Ka 1.7 x 10^ M"^) and about 50
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FIGURE 19. PSMA peptide inhibition assay. Forty pi of each peptide dilution 
was incubated with 40 pi of the MAb 7E11-C5.3 and then used as the primary 
antiserum for an ELISA assay with purified PSMA from LNCaP cells as the 
antigen. Peptides Nl. 19 ( • )  and N1.6 (O) competed in a dose dependent manner 
while the negative control peptide N669 (□) and peptides N334 (A),
N470 (▼), N583 (■) and N664 (A)were unable to block MAb 7E11-C5.3. The 
data represents the average of 3 independent experiments ± SE.
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fold higher than the N1.6 peptide (Ka 2.3 x 10^ M'^) although the affinity for 
N1.6 was only 7.4 fold lower than the affinity for N1.19.
6. BIOCHEMICAL ANALYSIS OF THE PSMA ANTIGENIC 
PEPTIDES. The synthetic peptide mapping clearly demonstrated MAb 7E11- 
C5.3 has a high affinity for the primary amino acid chain of PSMA. As a result, 
the ability of periodate to abrogate recognition of PSMA by 7E11-C5.3 (Fig. 10) 
was even more confusing. To determine if this decrease in antibody binding 
following periodate treatment of the purified PSMA resulted from the oxidation of 
the peptide backbone and not a carbohydrate, the synthetic peptides were treated 
with periodate prior to binding to the EIA plate for the direct binding assay. 
Periodate treatment of the active peptides N1.19 and N1.6 did result in a loss of 
MAb 7E11-C5.3 binding (Fig. 20, panel A). Additionally, to mimic the effects of 
periodate oxidation of the polypeptide chain, deletions and substitution of some 
key amino acids were synthesized. Peptide N2.6 (WNLLH) with a deletion of the 
methionine residue or NA1.6 (CWNLLH) with a substitution of cysteine for the 
methionine and peptide N1.5 (MWNLL) with a deletion of the histidine residue or 
N1.6 A (MWNLLY) with a substitution of tyrosine for the histidine residue were 
assayed in a direct binding assay. The deletion of either of these amino acids 
resulted in a loss of activity (Fig. 20, panel A) suggesting that they or at least the 
amino acids present in that position are important for the structure of the epitope. 
Substitution of either the methionine at position 1 with cysteine or the histidine at 
position 6 with tyrosine also resulted in a loss of activity (fig 20, panel A) 
indicating that the amino terminal methionine and the carboxy terminal histidine 
are required for structural integrity of the PSMA epitope and are essential for MAb 
7E11-C5.3 activity which, if lost by oxidation, would result in an abrogation of 
MAb 7E11-C5.3 binding.







B. MAPS N l.19 peptide
m
FIGURE 20. Analysis of the MAb 7E11-C5.3 epitope. (A) Peptides N1.19 and N1.6 
were treated with periodate as described for the native PSMA antigen. The activity of 
both peptides was reduced to background levels of the negative control (N669). Deletion 
of the methionine (N2.6) or histidine (Nl .5) and substitution of the methionine with 
cysteine (NA1.6) or substitution of the histidine with tyrosine (Nl .6 A) resulted in a 
similar loss of activity. (B) A MAPS N1.19 peptide was treated with 1) no treatment 
(lane 1), in the dark for 1 hr. in 50 pi water (lane 2), acetate buffer (lane 3), and 
periodate in acetate buffer (lane 4). The N l. 19 peptide was affected by only 
periodate treatments identically to the native PSMA molecule. The data represents the 
average of 3 independent experiments +/- SE.
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It was possible that periodate treatment of these small polypeptides may 
have been interfering with the ELISA assay and not oxidizing the amino acids. To 
control for this possibility, a N 1.19 multiple-antigen-peptide-system (MAPS) 
peptide containing 4 linear peptide chains per molecule was analyzed by Western 
blot analysis following treatment with periodate (Fig. 20, panel B). The reactivity 
of MAb 7E11-C5.3 to this N1.19 MAPS peptide (lane 1) was not reduced by 
incubations in water (lane 2) or acetate buffer (lane 3) but was abrogated by 
treatment with acetate buffer and periodate (lane 4). Therefore, the periodate and 
not the reaction buffers was responsible for the loss of activity.
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C. PHYSICAL CHARACTERIZATION OF THE PROSTATE SPECIFIC 
MEMBRANE ANTIGEN GLYCOPROTEIN.
1. PSMA EXPRESSION IN PROSTATE CELL LINES. The PSMA 
glycoprotein was detected predominantly as a 100 kDa band following western 
blot analysis of LNCaP xenograft tumor and cultured cell line membrane extracts. 
Occasionally, several additional bands were observed (Fig. 21) of approximately 
180 and 160 kDa. There was no difference in the expression of PSMA between 
the cultured cells and nude mouse tumors indicating that the use of cultured 
LNCaP provides a valid model to study PSMA. As is the case with other supposed 
prostate specific markers such as PSA, PSMA was not detected in any of the other 
prostate cell lines tested (Fig. 21). The 160 kDa band, as well as an occasional 70 
kDa band, were transient and most likely represented breakdown products of the 
two major species.
2. TWO DIMENSIONAL GEL ELECTROPHORETIC ANALYSIS OF PSMA.
To further characterize the PSMA expressed by the LNCaP cell line, two 
dimensional gel electrophoresis was performed using purified PSMA from in vitro 
cultured LNCaP cell membrane preparations. Surprisingly, identical isoelectric 
points for both species were observed with the major spots at isoelectric points of 
approximately 5.6, 5.7, and 5.8 for both the 100 and 180 kDa bands (Fig. 22). The 
tailing is consistent with the characteristics of integral membrane proteins. These 
results suggest the two species are very similar in their biochemical nature.
3. COMPARISON OF 100 AND 180 KDA BANDS. The fact that very 
similar isoelectric points were observed indicated that PSMA may exist in a dimer 
form. To look at this relationship more closely, LNCaP lysates were analyzed 
under a variety of denaturing and reducing conditions. The 180 kDa band was the






FIGURE 21. Western blot analysis of 50 pg of membrane preparations 
from LNCaP nude mouse tumors (lane 1), cultured LNCaP cells (lane 2), 
PC3 cells (lane 3), DU 145 cells (lane 4), and PPC-1 cells (lane 5). The 
100 kDa and 180 kDa PSMA bands are present in the LNCaP extracts 
but are absent in the other prostate cell lines
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PI
FIGURE 22. Two dimensional gel electrophoresis of affinity purified PSMA. Ten 
ug of purified PSMA was analyzed according to Materials and Methods. Arrows 
indicate the isoelectric points of 5.6, 5.7, and 5.8 showing identical spots for both 
the 100 kDa and 180 kDa bands.
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predominant species when LNCaP lysates were analyzed by Western blot without 
SDS or reducing agent (2-mercaptoethanol) in the sample buffer (Fig. 23 lane 1). 
The addition of SDS (lane 2) but not reducing agent (lane 3) was able to restore the 
migration of PSMA to 100 kDa. Next, affinity column purified PSMA was 
separated by SDS-PAGE and stained with coomassie blue. The two molecular 
weight species of 100 and 180 kDa are clearly evident (Fig. 24, lane 1). The two 
bands were excised, electroeluted from the gel then reapplied to an SDS-PAGE gel 
under reducing and denaturing conditions then immunoblotted with MAb 7E11- 
C5.3. The majority of the gel-purified 100 kDa band remained at the appropriate 
molecular weight (Fig. 24 lane 2). However, a minority of this band migrated at 
the higher molecular weight of 180 kDa. At the same time, the majority of the gel 
purified 180 kDa protein migrated at 100 kDa with a minority at 180 kDa (Fig. 24 
lane 3) which suggests that the two bands are identical.
To confirm the homology of the 100 kDa and 180 kDa species, partial 
tryptic digestion of the two bands followed by electrophoresis on an SDS-PAGE 
gel and silver staining resulted in identical banding patterns. This analysis 
indicated that the two bands consisted of the same molecule (figure 25).
4. COPURIFICATION OF A MITOCHONDRIAL PROTEIN WITH 
PSMA. A third major band of an approximate molecular weight of 40 kDa was 
co-purified with PSMA on a MAb 7E11-C5.3 affinity column when low detergent 
wash buffers were used on the column (Fig. 26 lane 1) but was not 
immunoreactive (lane 2). This band was blotted to nitrocellulose and subjected to 
amino acid sequence analysis. The amino acid sequence of the amino terminal end 
of this band was completely identical to the precursor form of the mitochondrial 
isoenzyme of aspartate aminotransferase (m-AST) also known as S-glutamic- 
oxalacetic transaminase (SGOT).
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AFIGURE 23. Western blot analysis of LNCaP cell lysates under different
reducing and denaturing conditions. 50 pg of an LNCaP cell lysate was 
prepared in sample buffer containing: 0% w/v SDS and 0% v/v 2Me (lane 1);
8% SDS and 0% 2Me (lane 2); 0% SDS and 20% 2Me (lane 3); and 8% SDS and 
20% 2Me (lane 4) prior to boiling and loading on a 4-20% gradient SDS gel and 
run under denaturing conditions. The PSMA glycoprotein was only seen at 100 kDa 
when the sample buffer contained SDS while 2Me was able to reduce approximately 
half of the 180 kDa band to 100 kDa.
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FIGURE 24. Purified PSMA was separated on an SDS-PAGE gel and 
stained with coomassie blue (lane 1) showing the predominant bands of 100 
and 180 kDa. The individual bands were excised and purified by 
electroelution from the gel slices. The gel purified 100 kDa (lane 2) and 180 kDa 
(lane 3) bands were then analyzed by Western blot showing the majority of both 
species migrating at 100 kDa indicating the 180 kDa band may be a dimer form 
of the 100 kDa species or that PSMA has a considerable amount of secondary and 
tertiary structure which is not easily reduced to the 100 kDa band.









FIGURE 25 Gel purified PSMA 100 kDa (lane 1) and 180 kDa (lane 2) bands were 
partially digested with trypsin then applied to an SDS-PAGE gel and run under reducing 
and denaturing conditions. The gel was silver stained to visualize the bands.
Both species gave identical peptide bands indicating they are homologous.







FIGURE 26. PSMA was purified from LNCaP by affinity chromatography and 
analyzed by gel electrophoresis and staining with coommassie blue (lane 1) and 
immunoblotting with MAb 7E11 -C5.3 (lane 2). the 100 kDa band is highly reactive 
while the 180 kDa band is less reactive. The 40 kDa band which co-purified with 
PSMA was not immunoreactive. This 40 kDa band was sequenced and was found 
to be 100% homologous with the mitochondrial subunit of SGOT-AST.
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5. DETECTION OF PSMA IN PROSTATE TISSUE. To investigate 
the expression of PSMA in prostate tissues, membrane extracts were examined by 
western blot analysis. Membrane preparations of normal, benign and malignant 
prostate tissues showed a Western blot banding pattern similar to that seen in 
LNCaP cell preparations except the migration of both the 100 and 180 kDa species 
had a slightly slower mobility of 120 and 200 kDa, respectively (Fig. 27A and 
27B, see arrows). This slower mobility of both bands was observed in all prostate 
tissue extracts analyzed with none showing the 100 and 180 kDa banding pattern.
The level of PSMA expression and the banding pattern in normal and 
primary CaP tissue extracts were similar with the predominant band being the 120 
kDa species (Fig. 27A). In most normal prostate tissue extracts, PSMA expression 
was consistent showing the 120 kDa species with a small amount of the 200 kDa 
band. Although some CaP tissues seemed to overexpress PSMA compared to 
normal tissues (fig 27A, lane 13), there did not appear to be a significant 
overexpression in the primary tumors. A difference in the level of PSMA 
expression and the banding pattern were observed in BPH tissue extracts (Fig. 27A 
lanes 6-9) compared to the normal and CaP tissues. BPH tissues expressed less 
PSMA and a more heterogeneous banding pattern with several tissues expressing 
only the larger 200 kDa species (Fig. 27B lanes 4 and 5). Figure 27B shows 
several of the tissue extracts which show a more heterogeneous expression of 
PSMA and a greater amount of the 200 kDa species. All prostate tissues examined 
expressed either the 120 kDa species, the 200 kDa species, or bothr. Little 
variation in the size of PSMA was noted between the three prostate tissue types 
except for some occasional smaller molecular weight species. For example, the 
smaller molecular weight bands in Figure 27B, lanes 2,3, and 4 may represent a 
degradation of the 120 and 200 kDa species, respectively.
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FIGURE 27. Expression of PSMA in prostate tissue. (A) Western blot of 50 pg of LNCaP
membrane extract (lane 1), normal prostate membrane extracts (lanes 2-5), BPH membrane
extracts (lane 6-9), and CaP membrane extracts (lanes 10-13). (B) Western blot analysis
of prostate tissue membrane extracts which show some of the heterogeneity
seen in some samples. Fifty ug of LNCaP membrane extract (lane 1), normal prostate
extracts (lanes 2,3), BPH tissue extracts (lanes 4,5), and CaP tissue extracts
(lanes 6,7). Arrows indicate the shift in the size of the bands from the 100 and 180 kDa
species observed in LNCaP to approximately 120 and 200 kDa in prostate tissue.
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6 . PSMA EXPRESSION IN NON-PROSTATE TISSUES. A panel of 
normal and malignant non-prostate tissue extracts was examined by Western blot 
analysis for PSMA antigen expression. The MAb 7E11-C5.3 was reactive with 
normal small intestine membrane extracts (Fig. 28, lane 2 and 3). Only a smear 
was seen when 50 pg was loaded (lane 2) but when less protein was analyzed (lane 
3) several bands were observed, although the pattern was unlike that in cultured 
LNCaP cells (100 and 180 kDa) or prostatic tissues (120 and 200 kDa). The 
vertical smearing of the lane is indicative of a heavily glycosylated protein. 
Additionally, a low yet significant expression of PSMA was observed in cerebral 
cortex and salivary gland (Fig. 28, lanes 4 and 5). The size of PSMA expressed by 
the cerebral cortex was similar to that seen in LNCaP cell line extracts 
(approximately 100 kDa) while the size of PSMA detected in the salivary gland 
was similar to that seen in prostate tissue extracts (approximately 120 kDa.) The 
PSMA glycoprotein was not expressed in the majority of non-prostate tissues 
examined including normal skeletal and cardiac muscle, colon, breast, lung, ovary, 
kidney, and liver tissues (Fig. 28, lanes 5-12) or a variety of non-prostate 
malignancies including colon, lung, bladder, liver and breast adenocarcinomas 
(Fig. 29, lanes 2-6).
7. SPECIFICITY OF THE MAb 7E11-C5.3 REACTIVE BANDS.
To determine if the multiple bands observed in prostate tissue extracts were 
specific or background artifacts, the N 1.19 active PSMA peptide was again used to 
competitively inhibit MAb 7E11-C5.3 reactivity in immunoblot assays. The 
reactivity to LNCaP cell line extracts, prostate tissue extracts and seminal plasma 
(Fig. 30a) could be totally eliminated by incubating the antibody with a twenty 
fold molar excess of the N l. 19 peptide (Fig. 30b).
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FIGURE 28. Expression of PSMA in normal non-prostate membrane extracts. Immun- 
oblot of membrane preparations from LNCaP cells (lane 1), small intestine (lanes 2 and 3) 
cerebral cortex (lane 4), salivary gland (lane 5), skeletal muscle (lane 6), cardiac muscle 
(lane 7), colon (lane 8), breast (lane 9), lung (lane 10), ovary (lane 11), kidney 
(lane 12), and liver (lane 13). All of the samples were analuzed at 50 pg per lane 
except for the small intestine sample in lane 3 which was 25 pg. The small 
intestine shows a smearing with no detectable bands similar to that seen in prostate 
tissue. The PSMA in the cerebral cortex (lane 4) is similar in size to the 
PSMA of LNCaP while the PSMA in the salivary gland (lane 5) is similar to that 
seen in prostate tissue.
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FIGURE 29. Expression of PSMA in non-prostate malignancies. Western blot 
analysis of 50 ug of membrane preparations from LNCaP cells (lane 1), colon 
adenocarcinoma (lane 2), lung carcinoma (lane 3), bladder carcinoma (lane 4), 
liver adenocarcinoma (lane 5), and breast adenocarcinoma (lane 6) showing 
the typical 100 kDa and 180 kDa bands in LNCaP cells but no expression 
in other malignant tissues.
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FIGURE 30. An immunoblot competition of MAb 7E11-C5.3 with the active PSMA 
peptides N 1.19. (A) Membrane extracts from LNCaP cells (lane 1), PC3 (lane 2), 
normal prostate (lane 3), BPH (lane 4), CaP (lane 5), and a seminal plasma from 
a prostate carcinoma patient probed with MAb 7E11-C5.3. (B) an identical blot probed 
with MAb 7E11 -C5.3 plus a 20 molar excess of PSMA N1.19 peptide. The N1.19 
peptide was clearly able to block MAb 7E11-C5.3 binding to its target antigen 
in prostate cell lines, tissues and seminal plasma.
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8. PSMA WAS NOT DETECTED IN THE SERUM OF PROSTATE 
CARCINOMA PATIENTS. Since other prostate markers are detected in 
significant concentrations in serum, I wanted to determine if  PSMA could also be 
detected in serum by Western blot analysis. Figure 31 shows the analysis of serum 
by Western blotting with MAb 7E11-C5.3. When these blots were exposed for the 
standard amount of time ( 1-2 min.) no bands were evident but when the blots were 
exposed for greater than 10 min. the pattern in figure 31A was observed. Lanes 1- 
3 represent LNCaP, normal prostate tissue membrane extracts and a normal 
seminal plasma, respectively. Note again the difference in the size of the PSMA 
expressed in LNCaP (Lane 1) as compared to the tissue and seminal plasma (Lanes 
2 and 3). The size of PSMA shed into serum would be expected to be similar to 
the size of PSMA observed in tissue extracts and seminal plasma. Serum from 5 
stage D2 CaP patients were pooled and analyzed in several ways. First, the serum 
was spiked with affinity purified LNCaP PSMA and incubated for 12 h at 37°C 
prior to analysis by Western blot (Lane 4). The PSMA in the spiked serum was at 
the expected molecular weights of 100 and 180 kDa identical to the PSMA seen in 
LNCaP extracts along with a larger band of unknown composition. Secondly, 29 
mg of the pooled stage D2 serum was solubilized and passed through a MAb 
7E11-C5.3 affinity column, washed and eluted from the column to remove the 
large concentrations of albumin and other proteins which make Western blot 
analysis o f serum difficult. No PSMA was detected in the affinity column eluant 
although a significant amount of serum proteins remained, particularly bands 
migrating at the expected molecular weights of the heavy and light 
immunoglobulin chains which may have adhered to the protein-A used to 
construct the affinity column (Lane 5). Thirdly, 400 pg of the same stage D2 
serum and 400 pg of a pooled BPH, a pooled normal male, and a pooled normal 
female serum (Lanes 6-9) were analyzed. Several bands were present following




FIGURE 31. Detection of PSMA in serum. (A) Western blot, using MAb 7E11-C5.3 
of 25 pg of LNCaP (lane 1) and normal prostate (lane 2) membrane extracts, 100 pg 
of a normal seminal plasma (lane 3), 400 pg of pooled serum from patients with 
stage D2 CaP spiked with purified PSMA (lane 4), 20 pg affinity purified pooled 
D2 serum (lane 5), 400 pg of the pooled D2 serum neat (lane 6), BPH pooled serum 
(lane 7), normal male pooled serum (lane 8), and normal female pooled serum (lane 9). 
(B) Western blot of 25 pg of LNCaP membrane extract (lane 1), 400 pg pooled D2 serum 
(lane 2) and 800 pg pooled D2 serum blotted with MAb 7E11-C5.3. (C) An identical 
blot probed with MAb 7E11-C5.3 plus N1.19 PSMA peptide. No PSMA was detected 
by affinity chromatography of the pooled D2 serum (panel A, lane 5) and while bands 
are present in the pooled serum, the same bands are present in the normal male 
and female serum. The bands in the LNCaP membrane extract were eliminated by 
competition with the Nl. 19 peptide while the bands in the pooled serum remained 
indicating that they are non-specific.
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overexposure of the blots in all the sera including the normal female serum but 
none at the expected molecular weight of 120 kDa.
The bands present in the pooled stage D2 serum did appear to be 
overexpressed as compared to the BPH and normal sera. The presence of identical 
bands in the pooled normal female serum suggested that the bands seen on this blot 
were non-specific. To determine if this were the case competitive blocking 
experiments were carried out. The D2 pooled serum was subjected to SDS-PAGE 
gel electrophoresis in duplicate along with an LNCaP membrane extract. One of 
the blots was probed with MAb 7E11-C5.3 and the duplicate blot was probed with 
MAb 7E11-C5.3 containing the N 1.19 PSMA peptide. Figure 3 IB shows the 
banding pattern for the LNCaP extract (lane 1) and 400 and 800 pg of the pooled 
D2 serum (lanes 2 and 3, respectively). There is a reactive band at the 
approximate molecular weight of 100 kDa in this pooled serum which could be 
interpreted to be PSMA. However, while all of the reactive bands seen in the 
LNCaP membrane extract were eliminated by the Nl-19 peptide competition (Fig. 
31C, lane 1) none of the bands in the serum were competed out (lanes 2 and 3). 
Additionally, an identical pattern could also be produced if  the pooled serum blot 
was probed with only the secondary antibody or with an isotype matched IgGj 
control antibody in place of MAb 7E11-C5.3 (data not shown).
14. DETECTION OF PSMA IN SEMINAL PLASMA. Since PSMA is 
a product of the prostate glandular epithelium, it was of interest to determine 
whether it could be detected in seminal plasma. Western blot analysis of seminal 
plasma obtained from normal (NSP), BPH (BSP) and prostate carcinoma patients 
(CaSP) showed PSMA was readily detectable in seminal plasma with expression 
of the 120 kDa band and occasionally the 200 kDa band similar to that seen in 
tissue extracts (Fig. 32). Normal seminal plasma showed the most consistent
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FIGURE 32. Expression of PSMA in seminal plasma. Western blot analysis 
of 50 pg LNCaP membrane preparation (lane 1), and equal protein concentrations 
(200 pg/lane) of normal seminal plasma (lane 2-5), BPH seminal plasma (lanes 6-9), 
and CaP seminal plasma (lanes 10-13). Lanes 1-9 represent an exposure time 
2 minutes while lanes 10-13 represent an exposure of 5 minutes. Note the slightly 
larger molecular weight of PSMA in seminal plasma compared to LNCaP.
The concentration of PSMA in normal seminal plasma (NSP) is consistent while 
it is quite variable in BPH seminal plasma (BSP). The PSMA concentration 
in Cad* seminal plasma (CaSP) appears to be lower than NSP but this likely 
results from the much higher total protein levels in CaSP as compared 
to both NSP and BSP resulting in a dilution of PSMA.
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expression of PSMA, with little variation from sample to sample, demonstrating 
the 120 kDa band and often an 80 kDa band (Fig 32, Lanes 2-5). BPH seminal 
plasma, similar to the BPH tissue extracts, exhibited variable expression of PSMA 
ranging from very low to overexpression (Fig. 32, Lanes 6-9). The majority of the 
CaP seminal plasma samples were similar in banding pattern to normal seminal 
plasma, although one sample showed only the 80 kDa band. While it appears that 
the concentration of PSMA in CaSP is lower than NSP, the total protein of these 
samples was significantly higher than NSP or BSP. In fact, when equal volumes 
of samples instead of equal protein concentrations were used for the immunoblots, 
the intensity of the CaP seminal plasma bands were comparable to those seen in 
the normal samples (data not shown).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
93
D. REGULATION OF THE PSMA GENE.
1. A MODEL FO R STUDYING STEROID HORMONE 
REGULATION. While several model systems are available to study the basic 
biology of the prostate, no suitable model has been described to study the 
expression of prostate specific genes. Therefore, a model system was designed in 
the present study using a prostate epithelial cell line which allowed for control of 
both the level of androgen receptor expression and the level of androgen hormone 
in the culture media (Fig. 33). The PPC-1 cell line which lacks endogenous 
androgen receptor expression (137) and PPC-1 AR5, a subline of PPC-1 containing 
an androgen receptor expression plasmid, were utilized as the basis o f this prostate 
epithelial cell model. The level of androgen receptor expression in the PPC-1 was 
below the detectable limits of Western blot analysis (Fig. 34, lane 2) while the 
PPC1-AR5 cells overexpressed the androgen receptor (lane 3) compared to the 
LNCaP cell line (lane 1). A breast adenocarcinoma cell line, BT-474, was utilized 
as a negative control (lane 4). Androgen hormones were removed from all tissue 
culture media by stripping the fetal calf serum of steroid hormones with charcoal 
dextran. The level of steroid hormones in this media was below the limits of 
detection of an RIA assay for testosterone and other androgen hormones (data not 
shown). To ensure that the PPC-1 cells could not synthesize DHT de novo from 
other hormones present in the media, finasteride was added to all media to inhibit 
the activity o f 5areductase. Hormone levels were then reconstituted with a stable 
synthetic analog of DHT, R1881, at a concentration of 1 which has been
shown to give maximal expression of the prostate specific antigen (PSA) gene 
under experimental conditions (130). The level of prostate gene expression could 
then be carefully analyzed in controlled conditions in a native prostate epithelial
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FIGURE 33. A model system for the study of prostate specific gene expression. The 
PPC-1 and PPC-1AR5 cell lines were used to control for the level of androgen receptor 
expression. To control for the level of androgen hormones, the tissue culture media was 
supplemented with calf serum depleted of steroid hormones then R1881 was selectively 
added to the media to reconstitute the level of DHT.
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FIGURE 34. Western blot analysis of androgen receptor (AR) expression in cell lines.
50 ng of whole cell lysates from LNCaP (lane 1), PPC-1 (lane 2), PPC-1 AR5 (lane 3), 
and BT474 (lane 4) were immunoblotted with an anti-androgen receptor antibody. The 
normal level of AR expression was observed in the LNCaP cell line while it was 
undetectable in both the PPC-1 and BT474 cell lines. The AR was overexpressed in the 
PPC-1 AR5 cell line containing the AR expression plasmid.
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cell environment under the four conditions possible with these two variables (Fig. 
33).
2. CLONING OF THE PSA PROMOTER. To ensure that the model 
system described above functioned as hypothesized, the 5’ flanking region (655 
bp) o f  the PSA gene was cloned as a control from human genomic DNA by PCR 
amplification and inserted into a pGEM-T vector. The cloned fragment was 
sequenced to verify its homology with the reported PSA sequence and was found 
to be 100% homologous. The fragment was subcloned into a basic CAT reporter 
gene vector containing no endogenous promoter activity.
3. CLONING OF THE 5’ FLANKING REGION OF THE PSMA 
GENE. A 700 bp probe from the 5’ end of the PSMA cDNA was used to screen a 
human genomic library for clones containing the promoter region of the PSMA 
gene. One clone with an insert of approximately 15 kB (PSMG4.22) was isolated 
and analyzed by restriction digestion and Southern blot analysis using a probe 
designed from the 5’ untranslated region of the PSMA cDNA to identify fragments 
with a high probability of containing the 5’ flanking region of the PSMA gene. A 
fragment of approximately 1 kB showed a strong hybridization with this 5’ probe 
(Fig. 35, lane 4) and was subcloned and partially sequenced. The 3’ end of this 
fragment contained 121 base pairs of the PSMA cDNA with the remaining 
sequence being upstream of the transcription start site (Fig. 36). The 5’ fragment 
contained no GC rich region and did not have a consensus TATA box but an A-T 
rich region was present at -30 to -60 (Fig. 36). As shown in figure 37, the entire 1 
kB fragment was subcloned into the basic CAT reporter gene vector (pCATbasic) 
in a forward (PSMG4.22CAT)and reverse (PSMG4.22RCAT) orientation and was
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FIGURE 35. Cloning of the PSMA 5' flanking region. Southern blot 
analysis of restriction fragments from the PSMG4.22 genomic clone showing 
the PSMA cDNA digested with Xho I and Pst I (lane 1), pGEM7Zf+ 
plasmid DNA (lane 2), PSMG4.22.5 5 kB Bam HI fragment subcloned into 
pGEM7Zf+ (lane 3), the 1 kB PSMG4.22 5' flanking DNA fragment 
(lane 4), and undigested parental PSMG4.22 genomic clone. The blot was 
probed with a probe from the 5' end of the PSMA cDNA.
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FIGURE 36. Restriction analysis of the 1 kb PSMG 4.22 
5' flanking DNA fragment. The flanking DNA does not have 
a consensus TATA box or G-C rich region but does contain a very 
A-T rich region between -30 and -60. A glucocorticoid responsive 
element (GRE) is also present upstream of the A-T rich region. 121 
bp of the flanking DNA is homologous with the 5' untranslated region 
of the PSMA cDNA.










FIGURE 37. Promoter-CAT reporter gene constructs. The
reporter gene constructs utilized for transient transfections
of PPC-1 and PPC-1 AR5 cells including the pCAT basic plasmid vector
(pCATbasic), the PSA promoter fragment (PSA3CAT), the PSMA
5' flanking DNA fragment cloned in a forward direction (PSMG4.22CAT)
and the same fragment cloned in a reverse orientation (PSMG4.22RCAT).
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analyzed along with the PSA promoter construct (PS A3 CAT) for promoter 
activity.
4. ANALYSIS OF PROMOTER ACTIVITY. To study the regulation 
of this PSMA 5’ flanking region, transient transfections of pCATbasic, PSA3CAT, 
PSMG4.22CAT, and PSMG4.22RCAT were carried out in PPC-1 and PPC-1 AR5 
cells and grown under the four conditions described in figure 33 for 48 hr. Total 
RNA isolated from pools of three separate transfections were analyzed by an 
RNAse protection assay for the CAT mRNA and the protected fragments were 
separated on an 8% denaturing polyacrylamide gel. There was no detectable CAT 
mRNA following transfection of the CAT vector (Fig. 38, lanes 1-4) or the 
PSMG4.22RC AT construct (Fig. 38, lanes 13-16). The PS A3 CAT construct 
showed a low level of transcription when at least one of the variables was absent 
(Fig. 38, lanes 5-7) and showed a greatly enhanced expression when both the AR 
and R1881 were present (Fig. 38, lane 8) indicating that the model system was 
valid. The PSMG4.22CAT construct showed a moderate level of expression with 
little difference between the four conditions.




•  H HCfl
a <
-O U










































FIGURE 38. Promoter activity assay. The constructs shown in figure 37 
were transiently transfected into PPC-1 cells (AR-) or PPC-1 AR5 cells (AR+) 
in the presence or absence of the synthetic androgen R1881. The promoter 
activity of each construct was determined by an RNAse protection assay 
specific for CAT mRNA. The results are shown as a graph of the relative intensity 
above background levels (A) and in the form of the original autoradiograph (B). 
The vector control (pCATbasic) showed no promoter activity while the PSA 
promoter (PSA3CAT) showed maximal activity in the presence of both the AR 
and R1881 indicating that the model system functioned as theorized. The PSMA 
5' fragment (PSMG4.22CAT) did have activity and was equally active in all four 
experimental conditions. As a control, the PSMA 5' fragment cloned in the reverse 
orientation (PSMG4.22RCAT) showed no promoter activity indicating that 
the activity of PSMG4.22CAT was real and not due to background expression. The 
data represents the average of 3 independent experiments +/- SE.




Prostate cancer is the most commonly diagnosed adenocarcinoma and the 
second most common cause of cancer deaths in men in the United States (1). The 
number o f deaths attributed to prostate cancer is increasing at a rate of 
approximately 8% a year (1) which means that between 1995 and the year 2000,2 
million males will be diagnosed and roughly 300,000 men will have died in just a 
five year time span. Therapy options for prostate cancer have not improved over 
the past decade and remain limited with few model systems in existence which 
allow for the study of novel therapeutic modalities. In order to advance the 
treatment options for prostate cancer, novel strategies for diagnosis and therapy are 
needed to improve the life expectancy of patients diagnosed with this disease.
The use of monoclonal antibody directed imaging and therapy applications 
have shown great promise for improving the survival of prostate cancer patients. 
However, improvements such as increased sensitivity and specificity must be 
realized before many of these models prove efficacious enough to be utilized for 
clinical applications. These improvements are entirely dependent on an in depth 
understanding of the monoclonal antibody, the antigenic epitope recognized by the 
antibody, and the molecule which carries the epitope. With this knowledge in 
hand, informed modifications may be made to improve existing applications. The 
present study has attempted to provide a foundational knowledge of the MAb
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7E11-C5.3 and the PSMA glycoprotein so that improvements in MAb 7E11-C5.3 
mediated diagnostic and therapeutic strategies may be realized.
The MAb 7E11-C5.3 was first described in 1987 (83). Since then, the 
antigen recognized by MAb 7E11-C5.3 has been described in some detail (84-92) 
and has been named the prostate specific membrane antigen or PSMA (88).
PSMA is a new prostate biomarker which appears to be overexpressed in poorly 
differentiated and metastatic prostate carcinomas (138). Antibody-radionuclide 
conjugates have been successfully used to localize metastatic disease in vivo 
(99,100) and treat human prostate tumors in nude mice (139). These reports 
suggest PSMA may have promise as an important new diagnostic and therapeutic 
tool for prostate cancer. Many questions about PSMA remain to be answered 
however, such as: (1) the exact localization and biochemical nature o f the epitope; 
(2) whether PSMA can be detected in tissues and body fluids, and if so what 
molecular forms are present; (3) the exact physical characteristics o f the PSMA 
glycoprotein; (4) and the regulation of the expression of the PSMA gene. The 
answers to these questions may allow for dramatic improvements in the in vivo 
diagnostic and therapeutic protocols. For example, based on the characterization 
of the MAb 7E11-C5.3 epitope, the sensitivity o f these assays may be increased by 
generating new antibodies directed against different domains of PSMA.
The present study has attempted to address these key questions by 
providing: 1) an in depth analysis of the localization of the MAb 7E11-C5.3 
epitope on PSMA; 2) definitively determining the composition of the antigenic 
epitope; 3) describing in detail the expression of PSMA in prostate cell lines, 
prostate and non-prostate tissues and body fluids; and 4) to understand the 
regulation of the PSMA gene at the molecular level.
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The localization of the MAb 7E11-C5.3 epitope on PSMA was definitively 
shown to be intracellular by immunofluorescence microscopy of living LNCaP 
cells. This finding was suprising in light of the ability o f 11 'indium labeled MAb 
7E11-C5.3 (CYT-356) to image occult tumors in vivo. It was clear however, the 
only mechanism which allowed for staining of LNCaP cells with this MAb was 
permeablization of the cell membrane while the OKT-9 MAb, which recognizes a 
well characterized transferrin receptor epitope on the extracellular face of the 
plasma membrane (140), readily stained LNCaP cells without fixation or 
permeabilization. This fact strongly argues for an intracellular 7E11-C5.3 epitope. 
How then is CYT-356 able to image occult tumors? While there is no definite 
answer to this question, it is doubtful CYT-356 is able to cross the plasma 
membrane since 7E11-C5.3 was not able to do so in vitro. Due to the propensity 
of prostate cells to enter apoptosis (141), the most probable answer is that a 
significant number of cells within a tumor may be lysed following cell death 
thereby uncovering the antigenic epitope. The number of apoptotic cells within a 
tumor may be substantially increased if the patient is on hormone ablation therapy 
since withdrawal of androgen hormones induces apoptosis (142) which may lead 
to an increase in the number of epitopes available to be recognized by CYT-356. 
Alternatively, as a tumor grows, a significant portion of the tumor volume may 
become necrotic (143) allowing for access to the intracellular epitope. Both of 
these mechanisms would result in CYT-356 “seeing” only a small percentage of 
the cells within a given tumor mass resulting in a significantly low sensitivity. As 
a result, specific second generation antibodies generated against the extracellular 
domain of PSMA may dramatically increase the sensitivity of imaging assays by 
increasing the number of cells which can be recognized by the antibody. This 
increased sensitivity may result in the detection of smaller metastatic foci 
containing a large percentage of intact cells which would not be discovered by
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MAb 7E11-C5. It must be stated in any discussion of PSMA second generation 
antibodies however, that the MAb 7E11-C5.3 may be the most selective antibody 
for prostate tissue. It is highly likely that many of the monoclonal antibodies 
generated against the extracellular domain of PSMA may be crossreactive with 
other cellular antigens. Therefore, it may not be possible to greatly improve the 
sensitivity of PSMA imaging over that which is obtained using 7E11-C5.3
The staining of fixed and permeabilized LNCaP cells with MAb 7E11-C5.3 
resulted in a diffuse cytoplasmic pattern unlike that o f integral membrane proteins 
(transferrin receptor) or secretory proteins (PSA). This cytoplasmic staining 
pattern was reproducible utilizing both immunofluorescent and immunoperoxidase 
methods and, therefore, was not an artifact of the staining technique. It may be 
argued that the weak detergent permeablization of the cells prior to staining caused 
the cell membrane to dissipate resulting in the cytoplasmic staining pattern. 
However, cells stained with the OKT-9 MAb following an identical detergent 
treatment retained a symmetrical staining around the circumference of the cells 
indicating the detergent extraction was not sufficient to cause diffusion of the 
membrane components.
To begin to determine the intracellular localization of PSMA, LNCaP cells 
were partitioned into nuclear, cytoplasmic, and membrane components and 
examined for the presence of PSMA. The cellular subfractionation of LNCaP cells 
clearly demonstrated two pools o f PSMA; one pool in the LM fraction the other in 
the HM fraction with very little in either the cytoplasmic or nuclear fractions. One 
of these pools may be localized to the plasma membrane since the LM fraction 
contained a significant concentration of PSMA by both ELISA and western blot 
analysis. The other pool of PSMA was most likely inside intracellular organelles 
which are partitioned in the HM fraction. The rough endoplasmic reticulum (ER) 
may contain a significant number of plasma membrane proteins as they transit
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from the ER to the membrane. The concentration of these plasma membrane 
components in the ER may be enhanced if  there is a defect in trafficking of 
molecules through this pathway (144). Alternatively, PSMA may be found in the 
mitochondria of LNCaP cells since the mitochondria make up a significant portion 
of the HM fraction as judged by the detection of the mitochondrial specific Hsp60.
Immunoelectron microscopy of LNCaP cells showed that PSMA is indeed 
found at two locations. The MAb 7E11-C5.3 epitope on PSMA could routinely be 
found localized at the cytoplasmic face of the cell membrane substantiating the 
conclusion of an intracellular epitope. The only distinct positive staining in 
addition to the plasma membrane was found to be surrounding and within the outer 
mitochondrial membrane. A localization solely at the cytoplasmic face of the cell 
membrane would result in a ringed staining identical to that of an extracellular 
epitope. However, the additional localization to mitochondria would explain the 
cytoplasmic appearance of the staining at the light microscopy level. Positive 
staining for PSMA at both the cell membrane and mitochondria was observed 
utilizing both an indirect chromagen staining and a direct staining with a gold 
labeled secondary antibody. These identical results using multiple 
immunoelectron microscopy techniques as well as the negative staining by an 
isotype matched control antibody suggests the staining was specific.
While the controls for the immunolocalization experiments did suggest the 
conclusions were valid, it was necessary to prove that PSMA was found in the 
mitochondria of LNCaP cells. PSMA was detected by western blot in 
mitochondria purified utilizing a multiple step sucrose gradient purification which 
was proven to yield high purity mitochondria (121). While it is difficult to judge 
the purity of this mitochondrial preparation short of electron microscopic 
examination, the mitochondria were applied to the sucrose gradient twice to ensure 
adequate purification. It would seem unlikely that a small amount of
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contamination with other cellular membranes would give such a strong signal upon 
immunoblotting with 7E11-C5.3.
These data strongly suggest the PSMA glycoprotein is localized at the 
plasma membrane with the epitope facing the cytoplasm and within mitochondria. 
While one would not expect a relatively prostate specific glycoprotein to be 
localized to an organelle which is considered to be rather generic in its 
constitution, there is precedent for the localization of plasma membrane 
glycoproteins to the mitochondria. The Her2/neu oncogene product has also been 
shown to be localized at the plasma membrane and mitochondria (145). 
Interestingly, like PSMA, a large percentage of Her2/neu staining in prostate and 
breast carcinoma cells appears to be cytoplasmic in nature (58,59) and not 
localized solely at the plasma membrane. This observation would seem to suggest 
there is a significant amount of communication between the extracellular 
environment and intracellular organelles. It is likely that a monitoring mechanism 
exists which may modify the metabolic activity of the organelle and that a 
significant number of plasma membrane receptors, including Her2/neu and PSMA, 
may be involved in this process. While such a mechanism may not have been 
proposed ten years ago, a similar communication has been described between the 
mitochondria, peroxisomes and the nucleus (146) and during starvation, 
myocardial cells appear to have an adaptive interaction between the intracellular 
and extracellular environments (147). Additionally, many studies have been 
carried out in recent years on the organization of the extracellular matrix which 
have come to the conclusion that cells seem to be able to sense the macromolecular 
composition of the extracellular matrix and to modify their production of matrix 
components accordingly (148). These studies indicate that a considerable amount 
of communication occurs between the different cellular components. Therefore,
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the suggestion that PSMA may be involved in subcellular communication is not 
without precedent.
Additional evidence o f the interaction between PSMA and the mitochondria 
may be derived from the 40 kDa protein which was co-purified on a MAb 7E11- 
C5.2 affinity column. This protein was only co-purified when no detergent was 
added to the wash buffers on the affinity column which suggests that it was 
associated with PSMA but disassociated by detergent washes. This 40 kDa protein 
was not immunologically active by western blot analysis. When purified and 
sequenced by amino-terminal sequencing (performed at the University of Virginia 
protein sequencing laboratory), it was found to be 100% identical to the precursor 
form of the mitochondrial aspartate aminotransferase (m-AST) enzyme (149). The 
precursor form contains a short signal sequence at the amino terminus for 
recognition and transport to mitochondria which is cleaved off after transport to 
the mitochondria (150). Since only the precursor form was present, it may be 
possible that one role of PSMA involves the transport of mAST to the 
mitochondria.
The co-purification of the m-AST precursor molecule in addition to the 
localization studies suggested it may be possible that the transport o f m-AST to 
mitochondria was dependent on a signaling event at the plasma membrane. It was 
theorized that serum starvation of LNCaP cells may result in the localization of 
PSMA solely at the cell membrane with serum stimulation causing PSMA to move 
from the cell membrane to the cytoplasm. However, serum starvation or 
stimulation of LNCaP cells failed to alter the staining pattern of PSMA. It is just 
as plausible that a signal at the cell membrane results in a sequestration of PSMA 
at the membrane and if the ligand for PSMA is not present in the tissue culture 
media PSMA would remain spread throughout the cell. In fact, a detailed 
examination of MAb 7E11-C5.3 staining of prostate tissue showed some ductal
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epithelial cells to exhibit staining confined to the plasma membrane with no 
cytoplasmic staining (138). This staining pattern may reflect the presence or 
absence of a possible PSMA ligand which has not been duplicated in the in vitro 
studies.
The basic physical and biochemical analysis of the 7E11-C5.3 epitope on 
PSMA revealed that it was recognized in both a reduced and denatured form based 
on the activity of the antigen in mercaptoethanol and SDS respectively. The 
PSMA epitope was also highly susceptible to proteolytic digestion by a variety of 
proteases and susceptible to oxidation by periodate. These observations led to the 
initial conclusion that the MAb 7E11-C5.3 epitope on PSMA consisted of a 
glycopeptide (92). Treatment of antigens with periodic acid has been utilized 
successfully in the past to indicate the presence of carbohydrates in antigenic 
epitopes (95). In an attempt to determine the type of carbohydrate linkage in the 
7E11-C5.3 epitope, the antigen was treated with sodium borohydride to cleave 0- 
linked oligosaccharides and LNCaP cells were grown in the presence of 
tunicamycin prior to antigen preparation to inhibit the addition of N-linked 
polysaccharides to the nascent peptide chain in the endoplasmic reticulum.
Neither of these more specific treatments had any effect on MAb 7E11-C5.3 
activity which contradicts the original interpretation of the periodate results.
One possible explanation of these contradicting results was that the 
preiodate or the acetate buffer utilized in the treatments was affecting the ability of 
the antigen to adhere to the assay plate resulting in falsely reduced measurements. 
To ensure that the periodate was actually affecting the integrity of the PSMA 
epitope, purified PSMA was treated with the acetate buffer or acetate buffer 
containing periodate prior to western blot analysis (Fig. 10, panel B). This 
analysis proved that periodate was able to directly inhibit binding of MAb 7E11- 
C5.3 to PSMA while the assay conditions and buffers had no effect at all.
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Lectin binding experiments also indicated that carbohydrates were present 
in the epitope and that this carbohydrate moiety contained D-galactose in some 
form since only lectins which were specific for either monomeric or polymeric 
galactose were able to block MAb 7E11-C5.3 binding. But, as observed with the 
basic biochemical analysis, it was impossible to demonstrate specificity by either 
glycosidic digestion o f PSMA or by competitive inhibition experiments using 
specific monomeric or polymeric carbohydrates or aminosugars. Therefore, 
significant contradictions remained in the biochemical analysis of the MAb 7E11- 
C5.3 epitope with some evidence suggesting a glycopeptide epitope and others 
indicating that there was no carbohydrate component.
While much of the biochemical characterization of the epitope remained 
ambiguous, it was clear that the peptide chain contributed substantially since 
proteolytic digestion abolished 7E11-C5.3 activity. Peptide epitope mapping was 
therefore attempted to establish the identity of the 7E11-C5.3 epitope. Evidence 
existed which suggested that the antigenic epitope was intracellular (151). Since 
there were only 19 amino acids in the intracellular domain, peptides were 
synthesized to span this domain. Importantly, all of the peptides utilized in this 
study were at least 85% pure as judged by reverse phase high pressure liquid 
chromatography (HPLC) analysis. The direct and competitive inhibition assays 
clearly demonstrated the MAb 7E11-C5.3 epitope was located within this 
intracellular domain. Complete mapping of the peptide epitope with peptides 
synthesized with sequential deletions from the C-terminal end proved the minimal 
reactive peptide consisted of the first six N-terminal amino acids (MWNLLH). 
There was a possibility the small peptides were not bound to the microtiter plates 
as efficiently as larger peptides. However, the competitive inhibition assay (Fig.
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19) did not require the peptides to be bound and was an important control 
experiment to verify the observations in the direct binding assay.
The affinity of MAb 7E11-C5.3 for N1.19 (Ka 1.7 x 109 M '1) was
approximately 6.8 fold lower than the affinity for the native PSMA glycoprotein
(Ka 1.16 x 1010 M’1) while the affinity ofMAb 7E11-C5.3 for N1.6 (Ka 2.3 x 
8 110 M ' ) was 7.4 fold lower than the affinity for N 1.19. The direct assays used in 
this study were a convenient means of assaying MAb binding to peptides, which 
would otherwise be unable to adhere to the plastic of the assay plates. However, 
the peptides were covalently linked to BSA which may significantly alter their 
conformation as compared to the native PSMA. It is not surprising nor 
unprecedented then that the affinity constants for the peptides and the native 
antigen are slightly different (152). This difference may be explained not only by 
the effects of crosslinking of the peptides to BSA as discussed above but also in 
differences between the linear synthetic peptides and the native PSMA molecule 
which may have a significantly different conformation and carbohydrate content 
which may act to stabilize the epitope. Additionally, modifications of the amino 
acids in the native protein, such as acetylation or other post-translational changes, 
might further stabilize the antigenic determinant of the native PSMA. Although 
the affinity o f the N 1.6 peptide may be lower than N 1.19 and the native PSMA 
molecule for the same reasons as discussed above, the competitive inhibition 
studies suggested the smaller peptide does indeed have a lower affinity which most 
likely results from a destabilization of the antigenic determinant. Nevertheless, the 
epitope mapping studies clearly demonstrated that the epitope recognized by MAb 
7E11-C5.3 is composed of the primary peptide chain in the intracellular domain of 
PSMA and that the minimal reactive peptide consists o f the first six amino acids
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(MWNLLH). This reactive peptide is predicted to be located at the intracellular 
face o f the plasma membrane (88) supporting the immunolocalization data.
Epitope mapping data suggesting the epitope consisted of only the core 
peptide and did not contain a carbohydrate moiety would explain the failure of the 
sodium borohydride, tunicamycin, glycosidase treatments and specific 
carbohydrates to block the MAb 7E11-C5.3 activity. However, the periodate 
oxidation and lectin competitive binding experiments were still contradicting if the 
MAb 7E11-C5.3 only binds to the peptide chain. Although periodate oxidation 
has been successfully utilized to identify carbohydrate epitopes, oxidation of 
amino acids may also occur (96). The treatments utilized in this study (5 mM 
periodate for 1 hr. at 25°C) should have been mild enough to preclude damage to 
the polypeptide chain while non-reducing sugars and pyranosidically linked 
hexoses within the oligosaccharide chains would have been oxidized (97). Harsher 
conditions including longer incubations, higher temperatures, or higher periodate 
concentrations could have resulted in the destruction of the peptide chain in 
addition to any carbohydrate. Since methionine residues are particularly 
susceptible to periodate oxidation (96) the possibility existed that the PSMA 
peptide epitope was particularly sensitive to these treatments. This was 
particularly possible since all of the reactive peptides began with the very N- 
terminal methionine of PSMA making it even more subject to oxidative attack 
since there is no protection on the amino terminal end of this amino acid. 
Treatment o f the reactive PSMA peptides (N1.19 and N1.6) with periodate did, in 
fact, abrogate MAb 7E11-C5.3 binding in an ELISA assay and by western blot 
analysis o f a large molecular weight MAPS (multiple-antigen peptide system) 
N1.19 polymer indicating that the peptide chain itself was being oxidized.
The sensitivity of the reactive peptides to oxidation was further confirmed 
by either substitution or alteration of the methionine or the histidine residues
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resulting in a loss of antibody binding. Clearly, both the methionine and the 
histidine residues were essential for activity o f these peptides and were affected by 
periodate supporting the conclusion that the MAb 7E11-C5.3 epitope on PSMA 
consists solely of the peptide backbone and does not contain a carbohydrate 
moiety.
Based on the peptide mapping experiments, an alternative mechanism for 
CYT-356 localization of prostate tumors in vivo may be that a second low affinity 
peptide epitope exists within the extracellular domain of PSMA. Several peptides 
containing a similar motif to the N1.6 minimal reactive peptide were identified 
(N470 [MYSLVH]; N344 [MHIHST]; N583 [MVFELA]; AND N664 
[MNDQLM]), synthesized and tested for reactivity with MAb 7E11-C5.3. 
Although these peptides were not active by either a direct binding or a competitive 
binding assay, it is possible that CYT-356 may have a low affinity for any one of 
these peptides which might result in a detectable signal upon immunoscintigraphy. 
Clearly, more studies are needed to definitively determine how CYT-356 is able to 
image solid tumors.
While the peptide mapping experiments explained one of the conflicting 
results garnered from the biochemical characterization, the ability of lectins to 
inhibit binding of MAb 7E11-C5.3 to PSMA remained confusing. The ability of 
some lectins to block the MAb 7E11-C5.3 binding may have occurred as a result 
of non-specific steric hindrance since the native PSMA does contain a substantial 
amount of carbohydrate with the deglycosylated polypeptide having a Mr of 
84,000 and the fully glycosylated molecule having an Mr of 100,000 (89). 
Additionally, only lectins with a specificity for D-galactose were able to block 
MAb 7E11-C5.3 suggesting that there may be a significant amount of galactose 
present on the native PSMA glycoprotein although not necessarily in the antigenic 
epitope. If a number of D-galactose containing oligosaccharides were in close
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proximity but not directly in the antigenic epitope, the binding of lectins to these 
carbohydrate residues may mask the MAb 7E11-C5.3 epitope
The expression of PSMA in the LNCaP cell line indicates that it remains 
the only prostate adenocarcinoma model which expresses any of the known 
prostate specific markers. None of the other prostate cell lines expressed PSMA or 
PSA and since there was no difference in the expression of PSMA between nude 
mouse tumors and cultured cell line extracts, in vitro cultured LNCaP cells 
represent a valid model for the study of PSMA. The 160 kDa band shown in 
figure 21 was rarely observed, but the 180 kDa band was frequently present in 
addition to the principal 100 kDa band. Two dimensional gel electrophoresis 
demonstrated that the two major species are very similar based on nearly identical 
isoelectric points and tailing reminiscent of membrane glycoproteins. Analysis of 
purified PSMA under different denaturing and reducing conditions suggested that 
the 180 kDa species may be either a dimer or a form which retains a significant 
amount of secondary and tertiary protein structure. The fact that SDS alone in the 
sample buffer resulted in only the 100 kDa band being detected suggests that the 
180 kDa band represents an incompletely denatured form of PSMA. This 
nondenatured form may be a homodimer of two 100 kDa molecules, a heterodimer 
of one 100 kDa species and another unknown molecule (possibly m-AST) or 
simply a form with a significant amount of tertiary structure causing it to migrate 
at a higher than predicted molecular weight. Reducing agents were not sufficient 
to reduce the 180 kDa species to 100 kDa suggesting that there is not a significant 
amount o f disulfide bonding in the native PSMA molecule. Polyacrylamide gel 
purification of both the 100 and 180 kDa bands followed by analysis on an 
additional western blot again demonstrated that the two species were identical 
since the purified 100 kDa band showed both the 100 and 180 kDa species while 
the majority of the purified 180 kDa band migrated at the lower molecular weight.
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The fact that some of the 100 kDa band migrated at 180 following re-analysis 
argues against the possibility that the 180 kDa species is a heterodimer since the 
100 kDa band was gel-purified prior to re-analysis. Therefore, the 180 kDa band 
most likely represents a dimer of two 100 kDa species or is a monomer with 
significant secondary and tertiary structure. This assertion was supported by the 
tryptic digestion of the purified bands followed by silver staining which showed 
identical banding patterns. While the 180 kDa could be eliminated from western 
blots if the SDS concentration in the sample buffer was at least 8%, this band was 
observed when the amount of protein loaded on a gel was high which argues that 
the 180 kDa band represents an incompletely denatured form of the predominant 
100 kDa band. The possibility that the 100 kDa band represented a breakdown 
product o f the 180 kDa species does not stand up in light o f the facts that some of 
the 100 kDa band migrated at the higher molecular weight after re-anlaysis and 
that the PSMA cDNA encodes for a 100 kDa glycoprotein (89).
A predominant 120 kDa PSMA band was found to be present in prostate 
tissue extracts with an occasional observation of a second band of 200 kDa.
Similar to the observations of PSMA in LNCaP cell extract, the 200 kDa species 
was most often seen when there was a large amount of the 120 kDa band 
suggesting a strong relationship between the low and high molecular weight 
components. The finding of a 120 kDa and 200 kDa bands was in contrast to the 
100 kDa and 180 kDa bands found in crude membrane extracts and purified 
preparations from the LNCaP prostate carcinoma cell line. This slower mobility of 
PSMA in prostate tissue extracts may have resulted from a post-translational 
modification or an alternative splice variant. The fact that normal, BPH and CAP 
tissue extracts exhibited the same size components, either the 120 kDa band, the 
200 kDa band or both, indicates the PSMA glycoprotein recognized by MAb 
7E11-C5.3 is synthesized identically in normal and pathological prostate tissues.
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Interestingly, a splicing variant of the PSMA mRNA has been reported. However, 
the smaller splice variant would theoretically result in a truncated protein lacking 
both the intracellular 19 amino acids and the transmembrane domain. Based on 
the epitope mapping discussed above, this smaller splicing variant cannot be 
detected with MAb 7E11-C5.3 since its epitope is found within the intracellular 
domain. It is interesting that the PSMA gene may be producing products which 
cannot be currently detected. Comparisons between the level of PSMA mRNA 
and the PSMA glycoprotein are made difficult and suggest that additional probes 
are needed to differentiate the full length PSMA and the theoretical truncated form 
o f this glycoprotein. Since only one splicing variant has been found, the slightly 
different size of PSMA as detected by 7E11-C5.3 in prostate tissue and LNCaP 
cells most likely results from differences in post-translational modifications.
There were no apparent differences in the expression of PSMA between 
normal and malignant prostate tissues. The BPH tissues however, showed a lower 
level of the 100 kDa band and was variable from sample to sample. This variation 
is consistent with the observed reduction in PSMA mRNA (89) and PSMA antigen 
expression (138) in BPH specimens. The often low and variable expression of the 
120 kDa band in the BPH specimens may have resulted from a greater expression 
o f the smaller splice variant or post-translational modifications.
PSMA was reported to be detected in frozen sections of proximal tubules of 
normal kidneys (83), and Lopes et al. (84) described PSMA expression in cardiac 
and skeletal muscle by immunoperoxidase staining. The same immunostaining 
reactivity was observed in formalin-fixed paraffin embedded sections of these 
normal tissues (154). However, in the present study, PSMA was not detected in 
extracts of these same normal tissues by western blot analysis which suggests the 
immunoperoxidase staining was non-specific. This conclusion is consistent with 
the fact that 7E11-C5.3 antibody-isotope conjugates did not localize to skeletal
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
117
muscle in mice (8) or in monkeys (155). Immunoblot analysis did detect PSMA in 
extracts of normal cerebral cortex of the brain, normal salivary gland and normal 
small intestine. These latter results correlate with the finding of PSMA mRNA in 
brain and salivary gland and no PSMA mRNA in other normal tissues, including 
skeletal muscle (89). It is of interest to note that PSA has recently been found to be 
present in breast, colon, ovarian, parotid, kidney and liver tumors, normal breast, 
amniotic fluid and breast milk (21), as well as normal salivary gland (22) and 
normal endometrium (23). These results suggest PSA can no longer be regarded 
as being a specific biomarker of the prostate gland. In spite o f the detection of 
PSMA by western blot analysis, PSMA has not been detected by immunostaining 
of frozen sections (83,84) or paraffin embedded sections (154) of normal brain, 
salivary gland and small intestine. This disparity may be the result of masked 
antigenic epitopes in the tissue sections or that the expression was below the 
detection limits of the immunohistochemistry assay. By using more sensitive 
assays, PSMA, like PSA, may eventually be found to be present in a variety of 
human tissues. The possibility that PSA may have a broader function than its 
association with semen liquefaction (21) points to the importance of determining 
the function of PSMA.
The finding that different species of PSMA were detected in brain (100 
kDa) and salivary gland (120 kDa) support the hypothesis that the differences seen 
between PSMA in LNCaP cells and prostate tissue extracts may indeed result from 
a change in post-translational modification and is not an artifact of in vitro cell 
culture. The high molecular weight smearing and multiple banding pattern on the 
immunoblot of small intestine was a pattern markedly different from that which 
was observed in LNCaP cell extracts and prostate and non-prostate tissue extracts. 
The banding pattern was suggestive of a heavily glycosylated glycoprotein or 
mucin (156). It is possible that MAb 7E11-C5.3 binds to an epitope other than
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PSMA in the small intestine or the smearing may be due to non-specific binding of 
the antibody. Since the secondary antibody (used without the primary MAb 7E11- 
C5.3) did not bind blots of small intestine, it appears likely that MAb 7E11-C5.3 
specifically bound to a component in this extract. Additionally, PSMA may be 
glycosylated differently in the intestine resulting in the different banding pattern.
The significant detection of PSMA in the brain, salivary gland and small 
intestine by MAb 7E11-C5.3 raises obvious concerns regarding the efficacy and 
safety o f using MAb 7E11-C5.3 immunoconjugates for diagnostic imaging and 
especially antibody targeted therapy. These cross-reactivities, however, should not 
dampen efforts to fully understand the function and clinical potential this novel 
biomarker may have in the diagnosis and therapy of prostate cancer.
PSMA was not detected in serum by Western blot analysis. This 
observation was surprising since previous reports have suggested that PSMA could 
be detected in serum by an immunoassay (83) and by western blot analysis (157). 
Immunoblot analysis of serum in the present study resulted in multiple bands 
similar to those reported previously by Rochon, et al. but only after the blots were 
overexposed to the X-ray film. They identified a band of 116 kDa as the PSMA 
component. In the present study, a band between 100-120 kDa was also observed. 
Importantly, although it did appear that this band was slightly overexpressed in 
pooled stage D2 serum compared to normal and BPH serum, the same banding 
pattern was observed in both normal female and male serum, suggesting these 
bands resulted from non-specific binding with either the primary or secondary 
antibody or that PSMA is present and shed into both male and female serum from 
common PSMA expressing organs.
The PSMA glycoprotein is relatively stable in serum since purified PSMA 
spiked into the pooled D2 serum was detected after 12 hours at 37° C at the correct 
molecular weight of 100 kDa. Therefore, the failure to detect PSMA does not
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appear to result from degradation. Additionally, PSMA was not detected 
following the enrichment of serum over 200 fold by affinity chromatography 
suggesting that the failure to detect PSMA was not a result of a low concentration. 
When MAb 7E11-C5.3 was mixed with the specific PSMA peptide (N1.19) then 
used as a probe, the PSMA bands in the LNCaP cell extract were eliminated while 
all the bands in the serum samples remained. In fact, an identical banding pattern 
was observed when only the secondary antibody was used to probe the serum 
immunoblot. These results clearly suggest that the bands observed in serum are 
non-specific, probably the result of non-specific binding by the secondary 
antibody. Since Rochon, et al., did not compete the reactivity with purified PSMA 
or show results using only the secondary antibody, the 116 kDa band they reported 
as being PSMA is most likely a serum protein reacting with the secondary 
antibody. These results and conclusions do not negate the possibility that PSMA is 
shed into serum however. The failure to detect PSMA by western blotting may 
have been the result of degradation or masking of the antigenic epitope over long 
term exposure to the blood stream. Alternatively, PSMA may be shed into the 
serum by cleavage at the cell membrane leaving the transmembrane and 
intracellular domains which carries the MAb 7E11-C5.3 epitope in the cell which 
would negate its detection with 7E11-C5.3.
Since PSMA could not be detected in serum it was encouraging to note the 
detection of PSMA in seminal plasma which indicated that clinical assays for 
PSMA may be possible. The 120 kDa, the 200 kDa band or both PSMA 
components were found to be present in seminal plasma from normal donors and 
from patients with benign or malignant prostate tumors. The PSMA detected in 
seminal plasma from normal males and prostate carcinoma patients showed a 
consistent banding pattern while the banding pattern in seminal plasma from BPH 
patients varied greatly. A thorough statistical evaluation of PSMA detection in
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seminal plasma will be needed to determine if any correlation exists between 
PSMA concentration and prostate pathology.
Thus far, this study has shown that PSMA exists in tissues and seminal 
plasma as a predominant 120 kDa band; in contrast, PSMA was found as a 100 
kDa glycoprotein in extracts o f LNCaP cells. Occasionally, a dimer form of 
PSMA having a molecular weight o f 180 kDa (LNCaP cell extracts) or 200 kDa 
(tissue extracts, seminal plasma) was observed. The finding of PSMA in seminal 
plasma coupled with the overexpression of PSMA observed in poorly 
differentiated and metastatic prostate tissues (138), suggests that measurement of 
PSMA concentrations in seminal plasma might be used to predict and monitor 
tumor progression. Although Western blot analysis failed to detect PSMA in 
serum, further studies will be required to determine if  any form of PSMA is shed 
in serum. The production of second generation antibodies against different 
antigenic epitopes other than the one recognized by MAb 7E11-C5.3 may be 
required to develop a highly sensitive immunoassay in order to determine if PSMA 
is or is not present in serum.
Model cell lines for the study of adenocarcinoma of the prostate are rare in 
contrast to the prevalence of cell lines from other malignancies such as breast 
(158-160) and colon (161-163) adenocarcinomas. Only a few well described 
immortalized prostate cell lines exist such as LNCaP (164), DU145 (165,166), and 
PC3 (167,168). Of these cell lines, only LNCaP retains the expression of the 
prostate specific biomarkers PSA and PSMA (169,170). Additionally, the slow 
growth of LNCaP cells is similar to the large majority of primary prostate tumors 
(171) making it the best in vitro prostate cancer model. The other prostate cell 
lines noted above all contain gross karyotypic changes, do not express prostate 
specific markers and have growth characteristics more similar to highly metastatic 
tumors than primary adenocarcinomas. While the Dunning rat ventral prostate
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models offer an additional system to study prostate cancer, questions concerning 
the validity of utilizing a model derived from an animal which rarely gets prostate 
adenocarcinoma must be addressed. As a result, the LNCaP cell line represents 
the best model for the study of prostate cancer. Unfortunately, the LNCaP cell can 
not be utilized for the study of androgen regulated genes.
The level of androgen receptor expression in LNCaP cells is normal, 
however, the use of LNCaP cells for the study of androgen regulated gene 
expression is not an option since the receptor contains a point mutation which has 
been shown to confer much different specificities and binding kinetics to the 
receptor (177). Therefore, a model to study the expression of prostate specific 
genes needed to be constructed which would allow for the control o f the level of 
wild type androgen receptor and the level of androgen hormones while keeping the 
prostate epitheilial cell environment intact.
In the present study, the PPC-1 cell line (178-180) was utilized as the basis 
for the model system. Since this cell line did not appear to express the androgen 
receptor (137) a subline o f PPC-1 was acquired which contained an androgen 
receptor expression plasmid. This subline (PPC-1 AR5) overexpressed the wild 
type androgen receptor as compared to LNCaP cells. The hypothesis was that 
PPC-1 cells could be utilized to study the expression of genes in the absence of 
androgen receptor while PPC-1 AR5 could be used to study expression in the 
presence o f the androgen receptor. The assumption made in this model was that 
neither the transfection of the androgen expression plasmid nor the selective media 
altered the PPC-1 cells in any manner except to induce the expression of the 
androgen receptor. Any changes to the cells which result from the androgen 
receptor would be expected and desirable and should not interfere with the 
interpretation of these data since the control of the expression of prostate specific 
genes by the androgen receptor may be mediated in both a direct and indirect
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fashion. Therefore, it would be desirable to imitate as many of these androgen 
receptor mediated cellular changes as possible in PPC-1 AR5.
O f considerable concern however, was the fact that the parental PPC-1 cells 
do not express the androgen receptor but grow quite well in tissue culture and in 
nude mice (179). Alternative pathways for the expression of prostate genes have 
been shown to exist (81,82) which may result in expression of some genes under 
conditions where they would not be expected to be expressed. Since the PPC-1 
cells do not express PSA or PSMA, this concern may not be a valid one.
However, these alternative pathways were taken into consideration during the 
development of the experimental design and were controlled for by utilizing the 
PSA promoter to ensure that androgen regulated genes were only expressed at a 
high level when both the androgen hormone and androgen receptor were present.
The level of androgen hormones in this model system were manipulated by 
first removing all of the steroid hormones from the media components by 
activated-charcoal dextran stripping. The stripping was carried out three times to 
ensure the majority of the hormones were removed and the level of androgen 
hormones in the media was below the detectable limits of an RIA assay. 
Nevertheless, very low molar concentrations of these hormones may have a 
significant impact on the expression of regulated genes (181). In the proposed 
model, if  a small amount of these hormones were present and able to influence the 
expression of androgen receptor regulated genes, the PSA promoter would also be 
expressed and would indicate whether the model system was functioning as 
theorized. An additional concern was the fact that DHT, the active form of 
testosterone could be synthesized de novo from a large number o f testicular as well 
as adrenal hormones by a number of different pathways (182). The common step 
in all o f these pathways is the final conversion of testosterone to DHT by the 
enzyme 5a reductase. To inhibit de novo synthesis, Finasteride, a powerful
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inhibitor of 5a reductase activity (183-186) was added to all of the media 
components to ensure that no DHT was synthesized within the model system.
Reconstitution of the androgen hormone levels was achieved by 
supplementing the media with the synthetic androgen R1881. This synthetic form 
of DHT has virtually the same kinetics of binding to the androgen receptor as DHT 
(187-190) but is much more stable. Therefore, the direct effects of androgen 
action could be studied without concern of the breakdown of DHT or the effects of 
the catabolites of DHT degradation on expression.
The model system designed for this study allowed for an elegant 
examination of the expression of androgen regulated genes by permitting the 
transfection of control and experimental constructs in all four possible variations 
(AR- DHT-; AR+ DHT-; AR- DHT+; AR+ DHT+) giving precise control of both 
the androgen receptor expression and the androgen hormone levels. The PSA 
promoter-CAT construct (PSA3CAT) was an integral part of this model system 
since use of this control allowed for the determination that the model system was 
working as hypothesized. If any or all of the possible problems as described above 
were manifested in the model, the PS A3 CAT construct would have been 
transcribed at a high level under conditions other than when transfected PPC- 
1AR5 cells were treated with R1881.
The 1 kb 5’ fragment isolated from the human placental genomic library 
was clearly hybridized with a probe designed from the 5’ end of the PSMA cDNA. 
This 5’-flanking DNA fragment was found at the very end of the parental genomic 
clone and therefore, this study could not address any enhancer or other regulatory 
elements further upstream than -879. Partial DNA sequencing of the PSMA 5’ 
fragment showed that it did not contain a consensus TATA box, was not GC rich 
but did have an A-T rich region present at -30 to -60. Many TATA-less eukaryotic 
genes have been described in the literature (191-194). The overriding feature of
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these TATA-less promoters is that the majority contain G-C rich regions and all 
have recognition sites for transcription factors. Although the 5’ fragment isolated 
in the present study did not have a G-C rich region, the expression of PSMA 
mRNA has been shown to be stimulated or inhibited by a number of cytokines and 
peptide growth factors (195,196) arguing that the gene must contain recognition 
elements for transcription factors such as NFkB, API, and AP2. Many of the well 
characterized transcription factors are able to function without a TATA box in an 
unknown mechanism which is independent of an association with the TATA 
binding protein (TBP). Interestingly, the p53 tumor suppressor gene has recently 
been shown to upregulate both the typical TATA containing promoters and 
TATA-less promoters (197).
Reporter gene assays have been successfully utilized in the past to study 
promoter activity (198). Several different methods are commonly used but the 
most frequent assay is the CAT assay (199-202) which allows for the measurement 
of chloramphenicol acetyltransferase (CAT) activity following transcription and 
translation of the construct under the control of the experimental promoter. Since 
this assay usually measures the level o f CAT enzyme activity, the conclusions 
regarding the promoter activity are based on indirect evidence since the promoter 
must first be transcribed, the transcript must be translated, and the translated 
protein must be enzymatically active. Standard CAT activity assays may yield 
significantly false results due to the relatively long half life of the CAT protein.
As a result, the true transcriptional activity of the promoter may not be measured 
since these assays function at the post-translational level and when studying the 
hormonal regulation of a promoter, changes in transcription may be rapid and 
would be missed if only enzyme activity was measured. Other methods of 
measuring the expression of the reporter gene are to measure the CAT protein by 
western blot analysis or by directly measuring CAT mRNA levels. The
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measurement of mRNA levels would allow for a specific and sensitive 
determination of CAT expression at any given time point as a result of the rapid 
turnover of mRNA compared to the CAT protein and the true level of promoter 
activity can be directly measured. In the present study, a ribonuclease protection 
assay designed to specifically measure CAT mRNA was employed to study the 
regulation of the PSMA gene.
Transient transfections of the pCATbasic vector, the PSA3CAT, 
PSMG4.22CAT and PSMG4.22RCAT constructs were carried out under all four 
experimental conditions. The results from these experiments suggest that the 
model system developed for this study functioned as hypothesized. The 
pCATbasic vector transfections showed no expression of CAT mRNA while the 
PSA3CAT construct was highly induced when both the androgen receptor and 
R1881 were present. The low levels of PSA3CAT expression in the first three 
conditions (Fig. 38, lanes 5-7) may have resulted from several different 
possibilities. A basal level of expression may be present in the absence of 
androgenic stimulation resulting from a leakage of the promoter which may be 
endogenous or caused by the removal of PSA gene elements during construction of 
the promoter fragment into the pCAT vector which are necessary for proper 
transcriptional control. Alternatively, a very low level of androgen receptor 
expression may exist in PPC-1 cells that was not detected by western blot analysis 
which could have resulted in a low level of PSA3CAT expression. A low level 
expression of the receptor, coupled by minute concentrations of steroid hormones 
remaining in the stripped media could account for the level of expression seen in 
this experiment. Importantly, the approximately 6 fold increase in CAT mRNA 
expression in the presence of both the androgen receptor and androgen was very 
similar to previously reported studies on the PSA promoter (132). Therefore, it
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can be concluded that this model system functioned as intended and could be 
utilized to draw conclusions from experimental PSMA constructs.
The PSMG4.22CAT construct showed a low level o f promoter activity and 
was not affected by changes in either the concentration of androgen hormone or 
androgen receptor levels. Importantly, when the PSMA fragment was cloned in a 
reverse orientation (PSMG4.22RCAT) there was no transcription of CAT mRNA. 
This pattern o f PSMG4.22CAT transcription was unexpected since the PSMA 
mRNA in LNCaP cells has been reported to be downregulated in the presence of 
androgen hormones (89) and the PSMA glycoprotein may be slightly 
overexpressed in patients undergoing androgen ablation treatment (154), although 
definitive studies have yet to be carried out to substantiate both of these 
observations. However, since the PSMA gene does have a responsive element for 
androgen hormones (GRE), a differential expression of the PSMG4.22CAT 
construct was expected.
One explanation of this observation may simply be that there are additional 
elements within the PSMA gene necessary for proper transcription to occur. This 
possibility is likely in light of the fact that a 641 bp fragment cloned upstream of 
the CAT gene was incapable of transcribing the CAT mRNA (203) but when 
additional enhancers were added to the construct, CAT activity was detected (203). 
This observation argues that there are enhancer sequences between the 5’ end of 
this construct (-565) and the 5’ end of the fragment used in the present study (- 
879). Other enhancers either further upstream of -879 or within intron sequences 
of the PSMA gene may be required to mimic the in vivo transcription of the PSMA 
gene. Alternatively, additional GRE elements may be necessary since the 
synergistic effects of two GRE elements has been reported for other promoters 
(204).
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An alternative explanation for the observations of PSMG4.22CAT 
transcription may be that androgen hormones are able to regulate the PSMA gene 
in an indirect fashion. This hypothesis is probable since direct androgen 
stimulation o f responsive genes has only been reported to result in transcriptional 
upregulation and not inhibition (66-69) although indirect negative regulation has 
been described for TGF-P2 expression in LNCaP cells (205). A mechanism for 
indirect androgen suppression of transcription of PSMA may be that DHT 
upregulates the expression of other hormones which may negatively feedback on 
PSMA expression. The observation that the PSMA gene does not contain a 
consensus TATA box or G-C rich region makes it likely that recognition 
sequences for transcription factors are present within the promoter sequence.
Many of the known transcription factors are highly responsive to cytokine and 
growth factor signals and may lead to the downregulation of PSMA following 
androgen stimulation. In fact, PSMA mRNA expression has been reported to be 
sensitive to several growth factors and cytokines (206). Alternatively, the lack of 
responsiveness to androgen hormones, even in an indirect manner, may be a result 
of the PPC-1 model. The PPC-1 cells utilized for the model system may lack the 
expression of the growth factors or the transcription factors necessary to properly 
regulate the PSMA gene. Alternatively, the responsive elements for these factors 
may not be present in the 5’ fragment utilized in this study. But, since all of the 
previous studious have been carried out in LNCaP cells, the results garnered in the 
present study may reflect the true transcription of the PSMA gene while the use of 
the LNCaP cell line may have resulted in aberrant conclusions since alternative 
pathways for upregulation (82) and downregulation (81) of the expression of 
androgen regulated genes has been described in LNCaP cells.
In spite of the incongruencies between the previously reported results of 
PSMA mRNA expression and the present study, the promoter activity of the
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PSMA gene has been shown to be quite different from the simple regulation of the 
PSA gene. This observation suggests that the PSMA gene may be highly regulated 
by several different direct and indirect mechanisms. Such a high level of 
regulation of the PSMA promoter may make the use of this promoter for gene 
therapy applications difficult.
In conclusion, this study has added significant knowledge to the 
understanding of both the 7E11-C5.3 monoclonal antibody and PSMA. 
Furthermore, the results of this study support the concept that this glycoprotein is a 
unique prostate biomarker which may have promise as a target for novel diagnostic 
and therapeutic strategies. The impact of this study may be seen in the 
development of new second generation antibodies directed against the extracellular 
domain of PSMA in order to both enhance the in vivo imaging and therapy 
approaches and determine if PSMA is actually shed into the serum. Although a 
serum assay for PSMA may add yet another tool for the screening and diagnosis of 
prostate cancer, it is unclear whether any improvements in detection could be 
achieved over the PSA assays currently available. Additionally, a more thorough 
understanding o f the hormonal regulation of PSMA may allow for in vivo 
manipulation of PSMA expression prior to monoclonal antibody directed therapy. 
Additional studies will be required to determine the function of PSMA. 
Nevertheless, this study has provided a solid foundation on which to build a more 
thorough understanding of MAb 7E11-C5.3 based imaging and therapy 
applications as well as functional studies of the PSMA glycoprotein.




The objective of this study was to more fully understand the physical and 
biochemical nature of the PSMA glycoprotein recognized by the murine 
monoclonal antibody (MAb) 7E11-C5.3. The specific aims of this study were: (1) 
to determine the subcellular localization of PSMA; (2) to determine the 
biochemical and physical nature of the PSMA glycoprotein; and (3) to begin to 
understand the regulation of the PSMA gene.
1. To accomplish the first aim, the LNCaP cell line was analyzed by 
mechanical cellular subfractionation utilizing gradient density centrifugation and 
Western blot analysis to determine if  PSMA is a cytoplasmic, nuclear or 
membrane glycoprotein. Light microscopy analysis utilizing multiple techniques 
including immunoperoxidase and immunofluorescence microscopy was 
undertaken to begin to determine the localization of PSMA within the cell. Then, 
immunoelectron microscopy of LNCaP cells was carried out to definitively 
determine the subcellular localization of PSMA.
2. The second aim was addressed by repeating previously reported 
experiments where necessary to confirm the initial observations. Once these 
results were verified, additional studies were carried out to explain the conflicting 
results garnered from this biochemical characterization. Specifically, the question 
of why MAb 7E11-C5.3 reactivity to PSMA was abrogated by periodate oxidation 
while assays to determine the specific carbohydrate failed to decrease activity. To 
address this question, the MAb 7E11-C5.3 antigenic epitope on PSMA was
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mapped with synthetic peptides. The reactive peptides were then treated with 
periodate as described for the analysis of the native antigen to determine if  they 
were susceptible to oxidation which would lead to the false conclusion that the 
epitope contains a glycopeptide.
The characteristics o f PSMA expression in prostate cell lines, prostate 
tissues and exocrine products of the prostate gland, as well as non-prostate tissues 
and human serum was thoroughly examined by Western blot analysis. The 
physical characteristics o f PSMA were also evaluated using polyacrylamide gel 
electrophoresis under differing conditions to determine the physical nature of the 
PSMA glycoprotein.
3. To begin to understand the regulation of the PSMA gene, a suitable 
model system had to be developed to study the expression of prostate specific 
genes. A model system was designed utilizing the PPC-1 primary prostate 
carcinoma cell line and which allowed for the control of both the level o f androgen 
receptor expression and the concentration of androgen hormones in a prostate 
epithelial cell. The PSA promoter was cloned and utilized as a control for 
androgen upregulation in these experiments. In order to isolate the 5’ flanking 
DNA from the PSMA gene, PCR primers specific for the PSMA cDNA were used 
to amplified probes for the PSMA gene. These molecular probes were used to 
screen a human cDNA library to isolate the PSMA cDNA. A restriction fragment 
encompassing 700 bp of the 5' end of the cDNA was then used to probe a human 
genomic library and several PSMA genomic clones were identified. The genomic 
clones were mapped and sequenced, and a fragment containing approximately 
1000 bp upstream of the translational start site was cloned into a basic 
chloramphenicol acetyl transferase (CAT) reporter gene construct containing no 
endogenous enhancers or promoters. The PSMA 5’ flanking DNA or the PSA 
control constructs were transiently transfected into the model system described
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above and assayed for CAT mRNA expression to definitively determine if PSMA 
was regulated by dihydroxytestosterone.
PSMA was found to be localized at the inner face of the plasma membrane 
and within mitochondria in LNCaP cells. The MAb 7E11-C5.3 epitope was 
determined to consist of only the peptide backbone of PSMA and localized to the 
intracellular domain with a minimal reactive peptide of 6 amino acids 
(MWNLLH). PSMA was detected in normal, benign and malignant prostate 
tissues as well as normal small intestine, brain and salivary gland indicating that 
this marker is not as specific as once thought. Additionally, PSMA was detected 
in seminal fluid but not in serum using MAb 7E11-C5.3. Finally, the promoter of 
the PSMA gene was cloned upstream of a reporter gene construct which was 
expressed in androgen and androgen receptor free conditions indicating that the 
regulation of PSMA is markedly different from that of the prostate specific antigen 
(PSA). This study has provided a solid foundation on which to build a more 
thorough understanding of MAb 7E11-C5.3 based imaging and therapy 
applications and continues to suggest that PSMA is a novel and important new 
prostate biomarker.
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